

REVIEW

Open Access



Ten golden rules for optimal antibiotic use in hospital settings: the WARNING call to action

Worldwide Antimicrobial Resistance National/International Network Group (WARNING) Collaborators^{1*}

Abstract

Antibiotics are recognized widely for their benefits when used appropriately. However, they are often used inappropriately despite the importance of responsible use within good clinical practice. Effective antibiotic treatment is an essential component of universal healthcare, and it is a global responsibility to ensure appropriate use. Currently, pharmaceutical companies have little incentive to develop new antibiotics due to scientific, regulatory, and financial barriers, further emphasizing the importance of appropriate antibiotic use. To address this issue, the Global Alliance for Infections in Surgery established an international multidisciplinary task force of 295 experts from 115 countries with different backgrounds. The task force developed a position statement called WARNING (Worldwide Antimicrobial Resistance National/International Network Group) aimed at raising awareness of antimicrobial resistance and improving antibiotic prescribing practices worldwide. The statement outlined 10 axioms, or “golden rules,” for the appropriate use of antibiotics that all healthcare workers should consistently adhere in clinical practice.

Keywords Antibiotic therapy, Antimicrobial resistance, Antimicrobial stewardship programs, Hospital-acquired infections, Infection prevention and control, Systemic antibiotic prophylaxis, Surgical site infections

Introduction

Antibiotics are essential and life-saving medicines. However, improper use is pervasive. Ensuring appropriate antibiotic prescribing is a fundamental aspect of good clinical practice [1]. Since Sir Alexander Fleming's discovery of penicillin in 1928, antibiotics have revolutionized medicine and been instrumental in saving countless lives [2].

There are also substantial disparities in antibiotic usage worldwide. Whereas some regions face the challenge of excessive antibiotic use, other areas suffer from limited access to essential antibiotics [3]. This concerning

disparity creates a gap that jeopardizes the sustainability and safety of global antibiotic supplies, ultimately compromising access to effective treatments and leading to suboptimal prescription practices [4].

Effective antibiotic treatment is an essential component of universal healthcare. There is a global collective responsibility to use antibiotics appropriately to maintain their effectiveness. Pharmaceutical companies have few incentives to develop new antibiotics due to numerous scientific, regulatory, and financial barriers [5–8]. Thus, it is questionable whether industry will replace ineffective antibiotics in time.

Antibiotics are used commonly in acute care hospitals for the treatment of both community- and hospital-acquired infections (HAIs), as well as for surgical prophylaxis [9]. However, when prescribed incorrectly, antibiotics offer little benefit to patients while exposing them to risks of adverse effects [10]. Studies have

Worldwide Antimicrobial Resistance National/International Network Group (WARNING) Collaborators

¹ Department of Surgery, Macerata Hospital, Macerata, Italy



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

demonstrated that adverse events are associated with antibiotic therapy in up to 20% of patients receiving systemic treatment [11, 12]. These events, in turn, can prolong hospitalizations, cause additional clinic or emergency department visits and hospital re-admissions, and result in a need for additional hospital services [13] that increase hospital cost [14].

Optimizing inpatient antibiotic prescribing results in improved treatment effectiveness and patient safety, minimizes the risk of antibiotic-associated infections (e.g., *Clostridioides difficile* infection: [CDI]) and the selection and transmission of antimicrobial-resistant bacteria in individual patients within and across hospitals, countries, and globally [15].

We propose that clinical leaders drive antimicrobial stewardship and education programs to help standardize and improve prescribing behaviors. Furthermore, we argue that guidance on the appropriate use of antibiotics from clinical leaders within a specialty is vital to address the global threat of antimicrobial resistance (AMR).

We present 10 core principles for the appropriate use of antibiotics, which clinicians should always follow in their clinical practice (Fig. 1).

Methods

In January 2023, the Global Alliance for Infections in Surgery [16] established an international multidisciplinary task force with the aim of developing a shared vision regarding the need for appropriate antibiotic use in hospital settings to address the threat of AMR in particular antibacterial resistance. Two hundred and ninety-five experts from 115 countries on six continents participated, including specialists in anesthesiology, clinical pharmacology, critical care medicine, emergency medicine, epidemiology, global health, health policy and management, hospital pharmacy, infection prevention and control, infectious diseases, internal medicine, microbiology, nursing, public health, and emergency and general surgery.

Supporting documentation was identified through comprehensive searches conducted using PubMed and Google Scholar. The search identified articles published in English between January 2000 and February 2023. Two experts, who collaborated in drafting the initial manuscript, reviewed the selected articles. Subsequently, the first version was shared with the experts' group and was revised with the incorporation of additional references. The final document was reviewed thoroughly by

10 GOLDEN RULES FOR OPTIMAL ANTIBIOTIC USE IN HOSPITAL SETTINGS

- 1 Enhancing infection prevention and control
- 2 Prescribing antibiotics when they are truly needed
- 3 Prescribing the appropriate antibiotic(s) at the right time
- 4 Administering antibiotics in adequate doses and routes
- 5 Initiating, as soon as possible, targeted treatment based on the results of culture and susceptibility testing
- 6 Using the shortest duration of antibiotics based on evidence
- 7 Achieving source control by identifying and eliminating the source of the infection or reducing the bacterial load
- 8 Supporting surveillance of HAIs and AMR, monitoring of antibiotic use, consumption, and the quality of prescribing
- 9 Educating staff and improving awareness
- 10 Supporting multidisciplinary ASPs and enhancing collaboration of healthcare professionals from various disciplines

Fig. 1 The 10 “golden rules” for optimal antibiotic use in hospital settings, which clinicians should always follow in their clinical practice



Fig. 2 Worldwide Antibiotic Resistance National/International Network Group (WARNING)

each task force member to ensure accuracy, timeliness, and consensus. The project has been named WARNING (Worldwide Antibiotic Resistance National/International Network Group) (Fig. 2).

By adhering to the 10 core principles described, health-care professionals in hospital (and community) settings can support responsible and effective antibiotic use, mitigate the risks of adverse effects and AMR, and promote better patient outcomes in their clinical practices. To enhance awareness and promote best practices, we developed impactful iconography that conveys salient messaging, facilitates implementation, and enhances the retention and application of recommended principles and practices.

The global burden of antimicrobial resistance (AMR)

AMR occurs as bacteria, viruses, fungi, and parasites evolve antimicrobial defense mechanisms that reduce treatment efficacy and increase the risk of treatment failure, disease progression, severe illness, or death. However, misuse and overuse of antimicrobial agents, combined with ineffective infection prevention and control (IPC) practices, are recognized as major drivers of the increasing prevalence of AMR [1] (Fig. 3).

Although antibiotic-resistant infections are a recognized public health threat, and this call to action addresses the appropriate use of antibacterial agents, less is known about the burden of AMR fungal infections [1]. Fungal infections are increasing in frequency, largely because of the increasing size of the population at risk, which includes persons with cancer, those requiring transplants, persons living with human immunodeficiency virus infection or who are immunosuppressed due to disease or therapy, and critically ill patients. Invasive fungal infections are associated with considerable morbidity and death.

Recently, *Candida auris* has emerged worldwide as a multidrug-resistant (MDR) pathogen [17–19] whose high transmissibility, broad-spectrum clinical manifestations, and potentially high mortality have led the US Centers for Disease Control and Prevention (CDC) to classify it as one of five pathogens in its Urgent Threats category [20]. Data published recently by the CDC highlight that *C. auris* is spreading at an alarming rate [21] since it was first described in 2009 [22] as an invasive infection [23]. Infections due to *C. auris* have increased to the point of higher prevalence than the common fungal pathogen, *C. albicans*, at some centers

ANTIMICROBIAL RESISTANCE

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites no longer respond to antimicrobial agents making infections difficult to treat and increasing the risk of disease spread, severe illness and death.

AMR is a natural phenomenon occurring as microorganisms evolve. However, inappropriate use of antimicrobial agents as well as inadequate infection prevention and control practices are major drivers for the development and spread of antibiotic-resistant pathogens. Especially alarming is the rapid global spread of multi- and pan-resistant bacteria.




Fig. 3 Antimicrobial resistance

[24]. *Candida auris* is uniquely challenging due to five factors: high transmissibility leading to widespread outbreaks in numerous hospitals worldwide [25, 26]; a broad spectrum of clinical manifestations associated

with a mortality rate as high as 70% [26, 27]; environmental hardiness, including persistence for weeks on dry surfaces [28, 29]; difficulty identifying *C. auris* by microbiology laboratories [29]; and a high rate of MDR

PRINCIPAL MECHANISMS OF ANTIMICROBIAL RESISTANCE

- 1 Enzymatic modification or hydrolysis which inactivates the antibiotic
- 2 Alteration of the antibiotic target site, reducing binding capacity
- 3 Modification of metabolic pathways to circumvent the antibiotic effect
- 4 Overproduction of antibiotic target protein
- 5 Reduction of intracellular antibiotic accumulation by decreasing permeability or increasing active efflux of the antibiotic
- 6 Biofilm formation

Fig. 4 Principal mechanisms of antimicrobial resistance

and therapeutic failure [28, 30–32]. The environmental fitness of *C. auris* is associated with biofilm formation and production of proteinases and phospholipases [27, 33], in addition to environmental stress resistance and antifungal drug resistance.

Bacteria may be intrinsically resistant to one or more classes of antibiotics or may acquire such resistance. Bacteria have developed different resistance mechanisms to avoid antibiotic action (Fig. 4). In addition to intrinsic resistance mechanisms, bacterial pathogens can acquire resistance to antibiotics through either mutation of existing genes [34], or by acquiring new genes from other strains or species through horizontal gene transfer [34].

“Heteroresistance” describes the presence of subpopulations of bacterial cells with higher levels of antibiotic resistance than those of the rest of the population in the same culture [35]. Recent work indicates that heteroresistance is very common for several different bacterial species and antibiotic classes. The resistance phenotype is often unstable, and in the absence of antibiotic pressure, it can rapidly revert to susceptibility [36]. Heteroresistance occurs in both Gram-positive and Gram-negative bacteria. Its clinical relevance may be considerable, since more resistant subpopulations may be selected during antibiotic therapy. However, the use of nonstandard methods to define heteroresistance, which are costly and involve considerable labor and resources, precludes evaluating the clinical magnitude and severity of this phenomenon [35]. Since heteroresistance may

have serious implications in antibiotic therapy, the development of standardized criteria and protocols for detecting and measuring heteroresistance is essential.

Infections caused by AMR bacteria pose a global challenge [37]. In 2008, the “ESKAPE” acronym was coined to name those bacteria that may “escape” the effects of antibiotics including *Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii-calcoaceticus* complex, *Pseudomonas aeruginosa*, and *Enterobacter* spp. [38]. The list of AMR bacteria is no longer up-to-date, as *Escherichia coli*, *Mycobacterium tuberculosis* and *Neisseria gonorrhoeae* are currently among the most prevalent bacterial pathogens affected by AMR issues.

In 2012, the European Centre for Disease Prevention and Control (ECDC) and the CDC developed standardized nomenclature to describe acquired resistance profiles in bacteria [39]. MDR was defined as acquired non-susceptibility to at least one antibiotic in three or more antibiotic classes (e.g., cephalosporins, fluoroquinolones, tetracyclines). Extensively drug-resistant (XDR) bacteria were defined as non-susceptibility to at least one antibiotic in all but two or fewer antibiotic classes (bacterial isolates remain susceptible to only one or two classes). Pandrug-resistant (PDR) bacteria were defined as non-susceptibility to all antibiotics in all antibiotic classes (Fig. 5). These classifications provide a standardized nomenclature for categorizing and communicating resistance patterns of bacteria, aiding in surveillance,




Fig. 5 Classification of drug-resistant bacteria

research, and the development of appropriate tactics to combat AMR [40]. Kadri et al. [41] proposed a new category of Gram-negative bacteremia, that is difficult-to-treat, based on non-susceptibility to “first-line” antibiotics, generally beta-lactams or fluoroquinolones, that necessitates the use of second-line, often more toxic, agents.

AMR is a complex and multifaceted issue that involves not only humans, but also animals and the environment [42, 43]. On March 17, 2022, four international agencies, the Food and Agriculture Organization of the United Nations (FAO), the World Organization for Animal Health (WOAH), the UN Environment Programme (UNEP), and the World Health Organization (WHO), signed a groundbreaking agreement to strengthen cooperation and promote sustainable practices that balance and optimize the health of humans, animals, plants and the environment. The concept of “One Health” recognizes the interconnectedness of the health of people, domestic animals, and the environment [44]. Multisectoral collaborations and concerted global efforts across multiple health domains are needed to tackle AMR [45–48] (Fig. 6).

In 2015, the WHO published the Global Action Plan on Antimicrobial Resistance [49]. Its five goals include: Improving awareness and understanding of AMR through effective communication, education, and training; strengthening knowledge through surveillance and

research; preventing infection through effective sanitation, hygiene, and IPC measures; optimizing the use of antibiotics in human and animal health; and increasing investment in new drugs, diagnostic tools, vaccines, and other interventions. Member states committed to develop national action plans (NAPs) on AMR, which should be comprehensive, funded, and implemented with monitoring so that lessons learned can reshape priorities. Inter-country variability in economic and political resilience, and resource constraints, constitute a considerable barrier to implementation of the NAPs [50, 51]. Despite the strong commitment to addressing AMR, endorsement and implementation of NAPs have also been impeded by the prioritization of issues related to the coronavirus disease-2019 (COVID-19) pandemic [52].

There is increasing evidence that the pandemic accelerated the emergence and spread of AMR at least in hospital settings [53] particularly *Acinetobacter* spp. Langford et al. reported that more than 60% of patients with COVID-19 who had a bacterial infection harbored a highly resistant organism [54]. However, multiple limitations intrinsic to the interpretation of COVID-19 data prevent accurate quantification of its impact on the global epidemiology of AMR [55, 56].

Alarming levels of AMR have been reported in all countries, regardless of their average income level [57]. The 2019 pre-pandemic analysis, published in 2022 by




Fig. 6 One Health

Murray et al. [57], revealed AMR as a leading cause of death worldwide (204 countries and territories) with 4.95 million estimated deaths associated with bacterial AMR, including 1.27 million deaths attributable directly to bacterial AMR. Among the 23 bacteria studied, six (*E. coli*, *S. aureus*, *K. pneumoniae*, *S. pneumoniae*, *A. baumannii*, and *P. aeruginosa*) were found to be responsible for 929,000 deaths due to AMR and 3.57 million deaths total. Notably, methicillin-resistant *S. aureus* (MRSA) alone caused more than 100,000 deaths in 2019. AMR bacterial infections were associated with the highest infection-related mortality rates in sub-Saharan Africa, with 99 deaths/100,000 people. By comparison, in high-income countries, AMR was associated with 56 deaths/100,000 individuals. However, Murray et al. may have underestimated the true burden of AMR [58]. Modern medical therapies, including trauma care, oncologic surgical interventions and chemotherapy, organ transplantation, and other invasive procedures, require effective antibiotics to prevent and treat infection. Untreatable infections reduce the value of these medical interventions by impacting efficacy adversely, although this is difficult to quantify [58].

The true burden of AMR in low- and middle-income countries (LMICs) would remain unknown unless surveillance is resourced adequately [59]. In particular, bacterial identification and susceptibility testing are not performed routinely in LMICs, owing to a lack of personnel, equipment, and supplies; moreover, testing may represent an out-of-pocket expense for patients in some healthcare systems [60]. As a result, antibiotic therapy is mostly empiric and broad-spectrum antibiotics may be misdirected. The resultant suboptimal care of infections can lead to clinical failure, higher mortality, and increased AMR. Some progress has been made in LMICs over the last decade regarding data collection to inform AMR, and monitoring of antibiotic use. However, more must be done.

The COVID-19 pandemic has demonstrated that morbidity and mortality from infectious diseases disproportionately impact upon certain populations [61]. The measures recommended to control the spread of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), including social distancing and frequent hand washing, pose challenges for those living in densely populated communities with inadequate housing, poor sanitation, and limited access to clean water. The poorest people are particularly vulnerable to the threat of AMR, as poverty increases the risk of contracting infectious diseases and being exposed to antibiotics. A 2018 systematic review by Alividza et al. [62] highlighted the complex relationship between AMR and various dimensions of poverty, including education level, income, and housing and

water quality. Addressing these disparities will be crucial for reducing the burden of AMR and improving public health outcomes in vulnerable communities.

An important report from India (the 'Chennai Declaration') was published in November 2012, representing a major national step forward as a landmark commitment to antibiotic stewardship, with international importance and global implications [63]. Although there has been a national antibiotic policy in India since 2011, the recommendations were difficult to implement owing to a lack of a clear plan of action. The lack of impact of such a well-intentioned but difficult-to-implement policy gave rise in August 2012 to a meeting of Indian medical societies and national authorities to develop a 'roadmap' outlining the urgent actions required. The final declaration was released in November 2012. The effort represents an extraordinary example of national consensus and commitment that recognizes the clinical and public health issues of AMR.

Recognizing the gravity of AMR, the United Kingdom commissioned in 2014 a comprehensive analysis of this global problem [64]. The stunning finding of this report was that, provided no action was taken, AMR would result in as many as 10 million deaths by 2050. Separately, the World Bank warned that "*in the high AMR-impact scenario, an additional 24 million people could be pushed into extreme poverty by 2030*" [65]. Although there is undoubtedly a large clinical and public health burden associated with AMR, it is challenging to quantify the associated excess morbidity and mortality. Detailed, reliable data, preferably based on comprehensive, population-based surveillance from LMICs and high-income countries [66] will be needed to enhance AMR control measures.

In 2022, the Group of Seven (G7; Canada, France, Germany, Italy, Japan, UK, USA) issued the G7 Health Ministers' Declaration [67]. Their communiqué covered a range of topics but focused on four priority areas: (1) overcoming COVID-19; (2) future pandemic preparedness; (3) AMR; (4) and health risks from climate change [67]. In a subsequent communiqué, the G7 health ministers called AMR an "*urgent public health and socio-economic problem*" that may have global effects but could have a greater impact on LMICs. Acknowledging AMR as a shared responsibility, they committed together to "*taking further urgent and tangible action*" to address the issue. Among the actions, they pledged to establish new or improved national integrated surveillance systems on AMR and antibiotic use in human beings, animal husbandry, farming, and environmental sectors; promotion of appropriate antimicrobial use through stewardship; strengthening implementation of IPC programs across the One Health spectrum; and strengthening the research and

development pipeline for new antibiotics. This approach aims to achieve optimal health outcomes for people, animals, and the environment, while considering the diverse socioeconomic, political, and cultural contexts affecting AMR [68], including limited technical expertise, insufficient clinical and research laboratory infrastructure, other financial constraints, and necessary political commitment [69]. As effective antibiotics are a global public good on the verge of scarcity, AMR is rightly considered a serious threat [70]. Preserving antibiotics is a collective responsibility [8, 71].

On 13 June 2023, the European Council adopted a resolution calling for stronger EU action to combat AMR in human and animal health and the environment, employing a 'One Health' approach to AMR. The resolution encourages the prudent use of antimicrobial agents in human and animal health through a series of voluntary measures, with the aim of reducing AMR [72].

Antibiotic use in the hospital and community setting

Healthcare workers (HCWs) play a crucial role in combatting AMR [1]. Unfortunately, antibiotics are often prescribed inappropriately in human and animal health settings [73]. When prescribing antibiotics, understanding the differences among prophylactic, empiric, and targeted therapy can help ensure appropriate use and help prevent the development of AMR. *Antibiotic prophylaxis* refers to the antibiotic administration to patients without signs of infection, in order to prevent its occurrence. *Empiric antibiotic therapy* is prescribed to treat known or suspected infections based on the patient's symptoms and likely causative pathogens before definitive diagnostic test results, including antibiotic susceptibility testing, are available. *Targeted antibiotic therapy* is initiated based on microbial identification and susceptibility test results to identify the specific pathogen and ensure that the most effective (ideally, also the most cost-effective), least toxic, and narrowest spectrum antibiotic is used as therapy. Optimal targeted therapy requires early identification and characterization of bacteria. However, despite advancements in rapid microbial diagnostics, the turnaround time for microbiologic testing and reporting can still take up to 72 h, if it is available at all. As a result, clinicians often initiate empiric antibiotic therapies that can have negative consequences for patients' health and exacerbate the risk of AMR [74].

Although antibiotic decision-making is reported to be driven by different determinants in medical versus surgical settings [75], hospital antibiotic prescribing practices are often inadequate worldwide [76]. A point-prevalence survey of 33 hospitals in five Latin American countries (Cuba, El Salvador, Mexico, Paraguay and Peru) documented adherence to prescribing guidelines

in 68.6% of cases. Third-generation cephalosporins were the most frequently prescribed antibiotic class (26.8%), followed by carbapenems (10.3%) and fluoroquinolones (8%). Targeted therapy was achieved in only 17.3% of cases [77].

All clinicians must strive for improvement by incorporating antibiotic stewardship principles into daily practice [78]. Antimicrobial stewardship programs (ASPs) [79–81] should be integrated into all hospitals' quality improvement programs worldwide. ASPs promote responsible antibiotic use by improving the diagnostic decision-making process (now called *diagnostic stewardship*); emphasizing the importance of prescribing antibiotics only when needed; to the right patient and clinical situation, at the right time, in the right dose and interval, and for the correct duration [82–84]. ASPs also play a vital role in increasing awareness of HCWs and community members regarding AMR [85, 86]. Diagnostic stewardship is an integral part of ASPs and emphasizes the importance of selecting the right diagnostic tests for the right patient at the right time [87], encouraging the use of rapid molecular diagnostics to initiate targeted antibiotic therapy as soon as possible while avoiding excessive use of broad-spectrum antibiotics when not (or no longer) needed. However, equally important is accurate interpretation of test results to prevent overdiagnosis and unnecessary cost [88], and improving the diagnostic decision-making process overall, integrating all needed information (clinical, biologic, imaging).

Although 15 years have passed since the CDC, the Society for Healthcare Epidemiology of America (SHEA), and the Infectious Diseases Society of America (IDSA) published joint guidelines for the development of institutional ASPs, best practices for ASPs are still being defined and are likely to vary based on local practice patterns, policy, and available resources [89]. The preferred means of improving antimicrobial stewardship include a comprehensive program that incorporates collaboration among specialists and support staff within an institution. In this context, the direct involvement of all prescribers in ASPs can be highly impactful [90].

Thus, we present the following 10 principles for the appropriate use of antibiotics. These principles should be adhered to by all HCWs in their clinical practices, and they should be considered as core components of activity within ASPs.

Enhancing infection prevention and control (IPC)

It is crucial for all HCWs to adhere to evidence-based measures of IPC to prevent the occurrence of HAIs. Effective IPC education and training significantly reduce HAIs [91–94], the most common of which are surgical




Fig. 7 Healthcare-associated infections

site infections (SSIs), catheter-associated urinary tract infections, central line-associated blood stream infections, hospital- and ventilator-associated pneumonia (VAP), and CDI [95] (Fig. 7).

Patients with HAIs require additional diagnostic and therapeutic procedures, have prolonged hospital stays, incur additional costs, and may have high morbidity and mortality. Moreover, many HAIs are caused by MDR bacteria [96, 97]. In the contexts of quality care and mitigation of AMR, preventing HAIs becomes increasingly important. These infections are associated with worse outcomes and often require broad-spectrum antibiotics [98]. According to the ECDC, the burden of the six major types of HAIs in the European Union/European Economic Area, expressed in disability-adjusted life years, was higher than the combined burden of all 32 other communicable diseases surveilled by the ECDC based on data from 2011 to 2012 [99].

Many HAIs are preventable. A reduction in HAI rates of 35–55% has been documented by implementing multimodal prevention and developing a safety-oriented approach, regardless of the countries' income levels [100]. Despite this, HCWs adhere poorly to evidence-based IPC measures [95]. A prominent example is hand hygiene, considered an indicator of patient safety and quality of

care and the cornerstone of IPC in all healthcare settings. Numerous organizations, including WHO [101] and CDC [102], have published guidelines providing HCWs with specific recommendations to improve hand hygiene practices. Recently, SHEA, IDSA, and the Association for Professionals in Infection Control and Epidemiology (APIC) published practice recommendations for the prevention of HAIs through hand hygiene [103]. The *Five Moments for Hand Hygiene* were promulgated by WHO to encourage HCW adherence to hand hygiene recommendations and minimize the risk of infection and transmission [104] (Fig. 8).

Although hand hygiene is accepted universally as a cost-effective IPC measure, compliance remains unacceptably low. In a systematic review [105], reported compliance was ~40% (compared with the WHO benchmark rate of >80%) and was variable across hospital units/wards and HCWs, calling for multifaceted mitigation activities to foster concordance. All HCWs involved in direct or indirect patient care should recognize the importance of hand hygiene and the need to perform it without fail. Hand hygiene at the point of care is recognized as a best practice for promoting compliance at the moments when hand hygiene is most crucial. According to current best practice, hand hygiene products should be




Fig. 8 The five moments for hand hygiene

available at the point of care. This requires that a hand hygiene product be easily accessible and as close as possible—ideally within arm’s reach of where patient care or treatment is taking place [106].

SSIs remain the most common HAIs among surgical patients. They represent a major clinical problem in terms of morbidity, mortality, length of hospital stay, and overall direct and indirect costs worldwide. It is obviously important to improve patient safety by acting before, during, and after surgery to reduce the occurrence of SSIs [107–109].

In 2016, WHO published evidence-based guidelines on the core components of effective IPC programs, to be implemented both at the national and hospital levels [110, 111]. IPC measures were summarized in eight “core components” (Fig. 9). Since the landmark Study on the Efficacy of Nosocomial Infection Control (SENIC) program in the 1970s [112] revealed the effectiveness of an IPC program in reducing HAIs, a dedicated IPC program is considered of paramount importance in every hospital. It should be led by experts in IPC, in close collaboration with HCWs in all relevant areas [113].

Results of a WHO global survey designed to assess implementation of these programs in healthcare facilities worldwide have been published. This survey provides an important overview of IPC program implementation

in 4440 healthcare facilities (81 countries) across all six WHO regions and income levels. The findings identify strengths, gaps in IPC implementation, and key opportunities for improvement to inform ongoing global IPC improvement efforts, particularly in LMICs, which showed significantly lower IPC implementation [114].

With the common goal of reducing AMR, IPC programs and ASPs should be partners in reducing HAIs. Support from institutional leadership is crucial for the success of each program and both together, including an effective microbiology laboratory (capacity, funding, and infrastructure) to enable rapid diagnosis, effective communication tools, and appropriate use of technology, including electronic health records. IPC and ASP programs are based on similar models of interdisciplinary work and activities such as education, monitoring, and feedback. Integrating these interventions may reduce redundancy and align forces for maximal influence on HCWs. ASPs, when implemented in concert with IPC interventions in hospitals, particularly hand hygiene, are significantly more effective in reducing the development and spread of MDR bacteria than ASPs alone [115].

Containing the spread of antibiotic-resistant bacteria is challenging because of their propensity for human-to-human transmission [116]. Carbapenem-resistant *Enterobacterales* (CRE), *A. baumannii* (CRAB), and *P.*

THE 8 WHO “CORE COMPONENTS” FOR THE IMPLEMENTATION OF INFECTION PREVENTION AND CONTROL



Fig. 9 The 8 WHO “core components” for the implementation of infection prevention and control

aeruginosa (CRPA) are among the most difficult-to-treat bacteria due to a high prevalence of AMR. In 2017, the WHO published guidelines for the prevention and control of these bacteria in acute healthcare facilities [117]. The supporting systematic literature review was published in 2019 [118]. The most frequent interventions reported were contact precautions (90%); active surveillance cultures (80%); monitoring, audit, and feedback of measures (80%); patient isolation or cohorting (70%); hand hygiene (50%); and environmental cleaning (40%).

Vaccination deserves mention as one of the most impactful and cost-effective prevention measures. Vaccines are mostly used prophylactically, including post-exposure prophylaxis, to decrease the number of infectious disease cases, and thus antibiotic use and the propagation of AMR. Vaccines are also being developed against resistant bacterial pathogens that cause a substantial disease burden [119] such as MRSA and *P. aeruginosa* [120, 121]. Vaccines are commonly considered to impact AMR, either directly by preventing infection, thereby reducing the prevalence of the resistant pathogen and also antibiotic use, or indirectly by preventing non-bacterial primary infections (e.g., viral), which are often treated incorrectly with antibiotics [119]. *Haemophilus influenzae* serotype B (HiB), influenza, and

pneumococcal conjugate vaccines are examples demonstrating the effectiveness of vaccines in reducing antibiotic use and reducing AMR [122–124]. Specific to surgery, vaccination against *S. pneumoniae* (which is increasingly resistant to penicillin), HiB, and *Neisseria meningitidis* following splenectomy is effective in preventing overwhelming post-splenectomy infection that is usually caused by encapsulated organisms [125]. Moreover, immunization against measles prevents measles virus infection, which infection reduces preexisting antibodies offering protection from other pathogens [126]. New vaccines are under development and evaluation, offering possibilities to address life-threatening diseases and help further curb antibiotic use and mitigate AMR [127].

Prescribing antibiotics when they are truly needed

Clinicians prescribing antibiotics are faced with conflicting priorities. On the one hand, they must provide patients with the best possible treatment. On the other hand, they must preserve the efficacy of antibiotics, minimize opportunistic infections such as CDI, reduce the selection of resistant pathogens in individual patients, and prevent the continued global increase of AMR. These conflicts should be evaluated and balanced before prescribing antibiotics [34] (Fig. 10).

FINDING THE RIGHT BALANCE IN PRESCRIBING ANTIBIOTICS




Fig. 10 Finding the right balance in prescribing antibiotics

The intestinal microbiota has an important role in human health and can protect the patient against colonizing enteric bacteria [128], a phenomenon known as *colonization resistance*. The indigenous bacteria of the microbiome provide an important host defense mechanism by inhibiting colonization by potentially pathogenic bacteria. However, in certain circumstances, a patient's microbiota can be compromised, no longer protecting against colonization by opportunists.

Antibiotics exert selection pressure on the human microbiome, predisposing to AMR. Antibiotic use can have unintended consequences on commensal intestinal microbiota. Whereas susceptible bacteria are destroyed, the resultant ecologic vacuum promotes the overgrowth of pathogenic bacteria that may already be antibiotic-resistant [129, 130]. Moreover, antibiotics facilitate the transmission of resistance genes conferring resistance to other bacteria [131, 132] (Fig. 11), thereby increasing the risks of cross-transmission between patients [133, 134] and outbreaks of infections caused by MDR bacteria.

Many studies have evaluated the long-term effect on gut microbiota following a course of antibiotics [135–137]. To demonstrate the long-term effects of

antibiotics on the healthy microbiome, the effects of amoxicillin (500 mg) thrice daily for 5 days [138], ciprofloxacin (500 mg) twice daily for 5 days [139], and (second-generation cephalosporin) cefprozil (500 mg) twice daily for 7 days [140] were evaluated in healthy individuals. Changes in the microbiota persisted for up to 12 weeks after the end of the treatment, characterized by the incomplete restoration of microbial equilibrium and the emergence of MDR strains. Moreover, compared with parenteral antibiotics, oral agents result in higher concentrations of antibiotics in the intestine and larger numbers of MDR bacteria in the intestinal microbiota [141]. A study of ciprofloxacin (500 mg twice daily for 10 days) or clindamycin (150 mg four times daily for 10 days) on the fecal microbiota of healthy human beings for 1 year showed a profound impact on the diversity of the microbiome [141]. Changes in microbial equilibrium were most pronounced in the first month after treatment, but persisted until month 20.

The commensal intestinal microbiota plays a pivotal role in protection against CDI [142]. *Candida difficile* is rarely present in the gut of healthy adults (~3%) [143]. The correlation between antibiotic exposure and CDI has

HOW ANTIMICROBIAL RESISTANCE DEVELOPS




Fig. 11 How antimicrobial resistance develops

been demonstrated [144]. Disruption of normal intestinal flora consequential to antibiotic use provides an opportunity for *C. difficile* to proliferate and produce toxins [145]. Animal and clinical studies have shown that normal intestinal microbiota inhibits the expansion and persistence of *C. difficile* [146]. These alterations can be evident during administration and for several days after the discontinuation of an antibiotic [147], depending on the administered antibiotic and the person's microbiota. The risk of CDI is estimated to increase up to sixfold during and in the subsequent month after antibacterial therapy [34]. Although most antibiotics have been associated with CDI, clindamycin, amoxicillin-clavulanic acid, third- and fourth-generation cephalosporins, fluoroquinolones, and carbapenems pose the greatest risk [34].

Surgical antibiotic prophylaxis (SAP) is a crucial component of perioperative infection prevention [148, 149], particularly in clean-contaminated and contaminated surgical procedures with a high infection risk. SAP may also be indicated in certain clean procedures where SSI, even if unlikely, may have devastating consequences, such as procedures with prosthetic implants. Patients with medical conditions associated with a higher risk of

SSI, including immunocompromised individuals (e.g., neutropenia), patients with American Society of Anesthesiologists (ASA) score ≥ 3 , and obese patients. Despite SAP not being required before all surgical procedures, over-administration is frequent, contributing substantially to overall antibiotic consumption in surgical services. Elective laparoscopic cholecystectomy carries a low risk of SSI. Use of prophylactic antibiotics is not justified in patients undergoing elective, uncomplicated laparoscopic cholecystectomy. The role of SAP in patients undergoing open-groin herniorrhaphy or hernioplasty remains uncertain owing to conflicting results of generally low evidence quality [150–155]. International guidelines [156] recommend SAP in open-groin mesh repair in any patient in a high-risk environment.

Antibiotic therapy should be prescribed after a bacterial infection has been confirmed. Colonization by potential pathogens without associated signs of infection occurs frequently in certain patients (e.g., those with indwelling urinary catheters, endotracheal tubes for mechanical ventilation, chronic wounds). Appropriate evaluation requires obtaining a culture from these sites only when indicated, without contamination by the collection

protocol itself (superficial swab cultures and cultures of drains [157] and sinus tracts are inappropriate), and avoiding antibiotic treatment of a “positive” culture result without symptoms and signs of active infection [158]. Asymptomatic bacteriuria is a common scenario for which antibiotics are not recommended, yet it is often treated regardless. Patients with a urinary drainage catheter may have “positive” urine culture results owing to inevitable biofilm formation on the device. Numerous studies show that antibiotic treatment of patients with asymptomatic bacteriuria is not indicated except in specific circumstances, such as pregnancy or transurethral instrumentation, because it can increase the likelihood of subsequent urinary tract infections that can become resistant to common antibiotics [159, 160].

The use of antibiotics in the treatment of mild uncomplicated diverticulitis has been common, but is now being questioned. Mounting evidence suggests that mild uncomplicated diverticulitis is more likely to be an inflammatory rather than an infectious condition, questioning the appropriateness of antibiotic use [161]. Three randomized trials each showed that antibiotic treatment neither prevents complications or recurrences nor reduces symptoms or length of hospital stay [161–163], as did two prospective cohort studies [164, 165]. The results of these studies have led some experts to advocate against the routine use of antibiotics [166, 167].

Prescribing the appropriate antibiotic(s) at the right time

Once the treatment decision has been made, it is crucial to select the most appropriate antibiotic(s) for that specific patient (Fig. 12). The antibiotic selected for SAP should be active against the common bacteria causing SSIs in the specific procedure. SSIs in clean procedures are usually due to skin flora, including *S. aureus* or coagulase-negative staphylococci. Clean-contaminated and contaminated procedures can involve other bacteria, such as *E. coli*, other Enterobacterales, or anaerobes, depending on the flora of the mucous membranes incised.

The most common antibiotics used for SAP have been first- and second-generation cephalosporins (e.g., cefazolin, cefuroxime) [148, 149]. Cefazolin is the drug of choice for SAP before most procedures. It has proven efficacy, a suitable duration of action, activity against the bacteria commonly encountered in SSI, a reasonable safety profile, and low cost. Routine use of vancomycin in SAP is not recommended. Vancomycin may be considered for SAP in patients with known MRSA colonization or those at high risk therefor, such as in institutions with a high incidence of MRSA infections, patients after a recent hospitalization, dialysis patients, and patients admitted from skilled nursing facilities, based on national recommendations and local epidemiology.




Fig. 12 Selecting the most appropriate antibiotic(s) for a specific patient

The administration is determined according to the antibiotic half-life. For most frequently used antibiotics, such as cefazolin or cefoxitin, intravenous administration 30–60 min before incision ensures effective tissue concentrations at the time of incision [168]. Redosing during surgery is required when the operative procedure lasts for more than 4 h or there is > 1.5 L blood loss [149, 169]. Vancomycin should be administered within 120 min before the incision, and given over 1 h for a 1 g dose (longer, if the dose is higher). Redosing is generally not required for antibiotics with a long half-life (e.g., fluoroquinolones, metronidazole, vancomycin).

Regarding empiric therapy before causative bacteria and susceptibilities are known, the optimal antibiotic choice should be based on the infection source, expected pathogens, the patient's clinical condition, local epidemiology, and individual patient risk factors for MDR bacteria. Knowledge of patients' risk factors for MDR bacteria is essential [1]. Treatment guidelines informed by local epidemiology and resistance patterns should be developed and implemented consistently according to ASP principles. Identifying the correct antibiotic(s) for a particular patient can be complex. Although the susceptibility of bacteria involved in community-acquired infections is usually substantially higher and broader than those involved in HAIs, clinicians often recommend broad-spectrum antibiotics for severe community-acquired infections to avoid “missing anything”. Whereas the spectrum of activity may be appropriate in doing

so, the likelihood is over-treatment because narrow-spectrum antibiotics are equally effective in most cases. By contrast, for HAIs, the best course of action is empiric broad-spectrum therapy, including an antifungal agent in some circumstances [170, 171], with later de-escalation to tailored therapy once microbiology data are available [172, 173].

In 2017, the WHO Expert Committee on Selection and Use of Essential Medicines established the AWARe (Access, Watch, Reserve) classification of antibiotics to aid antibiotic stewardship efforts globally at all levels of care. This classification system groups antibiotics into the aforementioned three categories, based on treatment of common bacterial infections and their impact on AMR, focusing on the need for appropriate use. The AWARe classification [174] was updated in 2021 to include an additional 78 antibiotics that were not previously classified, bringing the total number of classified antibiotics to 258 (Fig. 13).

The “Access” category refers to the antibiotic of choice for each of the 25 most common infections. These antibiotics should be available at all times and places and should be acceptable and affordable. The “Watch” category includes most of the “highest-priority critically important antibiotics”, which are recommended only for specific indications. The “Reserve” category includes antibiotics that should only be used as a last resort (i.e., to treat MDR bacteria) and only when all other antibiotics have failed. WHO recommends reducing the use of




Fig. 13 AWARe classification

antibiotics in the “Watch” and in the “Reserve” groups, and increasing the access and use of antibiotics in the “Access” group, expecting 60% of all antibiotic use in hospitals should come from this group [174]. As a practical matter, this would reduce the global utilization of piperacillin-tazobactam, an antipseudomonal ureidopenicillin that is overused to treat community-acquired infections.

Assessing the severity of infection is a crucial step in evaluating patients for antimicrobial therapy. Early implementation of appropriate empiric antibiotic therapy has a significant favorable impact on outcomes of septic shock, independent of infection site [175]. Whereas critically ill patients benefit from early antibiotic therapy, clinicians managing less severely ill patients may have time to consider carefully and determine the appropriate antibiotic treatment before initiating therapy [175]. Delayed antibiotic prescription, using a wait-and-see approach with reevaluation of the patient, has been reported as a useful tactic to help reduce antibiotic use, particularly for respiratory tract infections [176]. However, some data suggest that hasty antibiotic therapy may be harmful for critically ill surgical patients, where the adequacy of source control is the crucial determinant of survival. A before-after trial [177] compared universal early antibiotic therapy (aggressive approach) to a second period where immediate antibiotic therapy was given only in hypotensive patients. At the same time, other patients underwent therapy only after microbiological confirmation of infection (conservative approach). The aggressive approach was associated with a lower time interval from fever onset and blood culture collection to the start of treatment. The conservative approach was associated with more likely initial appropriate therapy, a shorter duration of therapy, and lower mortality. This differentiation of infection from inflammation can be challenging, especially in critically ill patients, wherein only about one-half of suspected infections are proven. Delaying antibiotics to investigate the cause of sepsis may be of benefit to patients without shock.

Delayed antibiotic prescription is especially useful to help reduce antibiotic use, especially for community-acquired respiratory tract infections [178], many of which have a viral etiology. In a meta-analysis, delayed prescription compared with no antibiotics was associated with similar symptom duration; withholding antibiotics pending pathogen identification and susceptibility testing may be acceptable to reduce unnecessary antibiotic use for viral respiratory tract infections.

By contrast, for patients (both adults and children) with sepsis-related shock and organ dysfunction, delay of appropriate empiric antibiotic therapy can be deleterious [179, 180]; early initiation of antibiotics is crucial for good outcomes. There is a strong correlation between

each hour of delay in antibiotic initiation and mortality rates for patients with septic shock [181, 182]. The 2021 Surviving Sepsis Campaign guidelines recommend that adults with possible septic shock or probable sepsis should receive antibiotics as soon as possible, ideally within 1 h from symptom onset [183]. For adults with possible sepsis without shock, a rapid assessment for the likelihood of infectious vs. non-infectious causes of acute illness should be conducted, and antimicrobial agents should be administered within 3 h from the time sepsis was first recognized [183].

The involvement of MDR pathogens in HAIs is a risk factor for inappropriate empiric therapy and, as such, for adverse outcomes. Prior knowledge of colonization caused by MDR bacteria via surveillance cultures improves the likelihood of appropriate initial antibiotic therapy for subsequent HAIs in critically ill patients with blood stream infections or VAP [184, 185]. Additionally, as surveillance cultures have a high negative predictive value for MDR bacteria, early appropriate antibiotic therapy can have antibiotic-sparing potential by reducing use of carbapenems and other antipseudomonal agents compared with a hypothetical guideline-based prescription [185–188]. As such, antibiotic selection pressure on the local ecology may be reduced. A meta-analysis of diagnostic test accuracy revealed that a twice-weekly sampling frequency is the most efficient and that recent surveillance cultures have a higher positive predictive value for bacterial pathogens in VAP [185].

Administering antibiotics in adequate doses and appropriate routes

Administering antibiotics in adequate doses should be based on the intrinsic pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of each antibiotic class and the specific agent, and on the specific pathophysiological characteristics of the patient. Antibiotic PD refers to the relationship between the concentration of the drug and its ability to inhibit bacterial growth. The minimal inhibitory concentration (MIC) is the primary in vitro parameter used to assess the effectiveness of an antibiotic against its target bacteria. In order to obtain a therapeutic effect, the concentration at the site of infection should exceed the MIC against the target bacteria for at least 40% of the dosing interval, and ideally longer (if killing is time-dependent) or by >tenfold (if killing is concentration-dependent) [189]. Antibiotic PK describes how antibiotics are absorbed, distributed, metabolized, and eliminated from the body, which in turn determines the time course and concentration of antibiotics in serum and tissues and at the site of infection. Suboptimal concentrations at the target site may have important clinical consequences such as therapeutic failure and promotion

of AMR development, especially when clinical isolates have borderline *in vitro* susceptibility [190].

Clinical- and antibiotic-related factors can contribute to a differential distribution of antibiotics at the target site [191]. Knowledge of PK/PD of each antibiotic may provide a more appropriate definition of optimal dosing regimens in terms of both dose and administration interval [192]. The concentration gradient between plasma and the site of action may be of high relevance in cases of MDR bacterial infection. For example, data suggest that increased doses of ceftazidime, meropenem, and imipenem-cilastatin are required to reach target attainment in patients with severe intra-abdominal infections [193–195].

Critically ill patients are at high risk of infections, risking life-threatening sepsis and multiple organ dysfunction syndrome. The pathophysiology of sepsis and septic shock can have a major effect on PK parameters. Knowledge of pathophysiologic effects on PK/PD is essential for optimizing antibiotic treatment in critically ill patients with sepsis or septic shock [196, 197]. Hepatic or especially renal dysfunction are conditions where PK changes and dosage reduction may be needed.

The dosing frequency of an antibiotic is determined by the concepts of time-dependent vs. concentration-dependent activity. For example, beta-lactam antibiotics exhibit time-dependent activity, whereby optimal bactericidal activity is achieved when antibiotic concentrations are maintained above the MIC over prolonged periods of time. For this reason, the serum concentration of the antibiotics should exceed the MIC for at least 40% (optimally 70%) of the dosing interval [196]. Higher dosing frequency, prolonged infusions, and continuous infusions achieve this effect and optimize beta-lactam activity [196]. By contrast, antibiotics having concentration-dependent activity are ideally administered to achieve a high peak plasma concentration. For these antibiotics, the peak serum concentration:MIC, not the time above the MIC ($fT > MIC$), is more closely associated with efficacy [196]. Despite the ideal method of administration and the preferred dosing schemes of aminoglycosides being once-daily dosing for most therapeutic indications, especially in critically ill patients [198], aminoglycoside nephrotoxicity is due to their uptake saturation and a direct vasoconstrictive effect on the renal cortical microcirculation. Thus, limiting aminoglycoside exposure to the renal cortex, by limiting administration to once-daily, reduces the risk of nephrotoxicity [34, 199].

In patients with septic shock, administering a first “loading” dose is probably as fundamental as the timing of administration, depending on the antimicrobial agent [34]. The volume of distribution (V_D) of hydrophilic agents (such as beta-lactams, aminoglycosides, and

glycopeptides) in septic shock patients may be increased due to increased microvascular endothelial permeability, expanding the extracellular fluid compartment. Loading doses of beta-lactams, aminoglycosides (especially with once-daily dosing) or glycopeptides are recommended to maximize the therapeutic effect [196].

Once initiated, the antibiotic regimen should be reassessed at least daily, given that fluctuating organ function, common in critically ill patients, may substantially affect antibiotic exposure. For example, lower doses of antibiotics excreted in urine should be administered in the presence of impaired renal function, whereas higher than standard doses should be administered in patients with augmented renal clearance (e.g., burn patients, obesity) [34]. Antibiotic therapy represents a challenge for obese patients because of altered PK/PD [200]. Obesity increases V_D , especially for lipophilic antibiotics, which can lead to lower-than-expected plasma antibiotic concentrations. Augmented renal clearance is frequent. In addition, fatty infiltration of the liver may impair hepatic function. In general, regardless of body mass, the dosing of lipophilic antibiotics should be based on total body weight, or adjusted body weight for hydrophilic antibiotics. Individualized dosing, supported by laboratory testing, is essential owing to patient heterogeneity and clinical fluctuation.

Recently, a revised consensus guideline and review on therapeutic monitoring of vancomycin for serious MRSA infections was published by the American Society of Health-System Pharmacists, the IDSA, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. This consensus revision evaluates the current scientific data and controversies associated with vancomycin dosing and serum concentration monitoring for serious MRSA infections (including but not limited to bacteremia, sepsis, infective endocarditis, pneumonia, osteomyelitis, and meningitis) and provides new recommendations based on recent available evidence [201].

Oral antibiotic administration has been shown to decrease the cost and length of hospitalization [202, 203]. The general guidance for the timing of intravenous-to-oral switching of antibiotics provided the gastrointestinal tract is functional, includes defervescence and clinical improvement with or without improvement in laboratory markers [204]. Numerous antibiotics with high oral bioavailability can be considered for switching, and the switch need not be to the same agent. Many serious infections can now be treated successfully with partial oral antibiotic therapy [205]. However, the switch to oral antibiotics should not lead to an antibiotic therapy which is longer than that used for parenteral therapy. Actually, it is increasingly evident that prescribing oral antibiotics

could influence gut microbiome dynamics, promoting more strongly AMR [206].

Initiating, as soon as possible, targeted treatment based on the results of culture and susceptibility testing

Microbiologic tests play a crucial role in selecting targeted antibiotic therapy. This testing allows clinicians to tailor the spectrum of the antibiotic, broadening if the initial choice was too narrow, but more commonly narrowing an empiric regimen spectrum that was too broad, known as *de-escalation*. Antibiotic therapy reassessment based on microbiologic culture and susceptibility testing supports ASP and is associated with improved outcomes in severe infections [34].

The de-escalation tactic involves transitioning from a broad-spectrum empiric antibiotic regimen to a narrower-spectrum regimen, or reducing the number of antibiotics used in combination therapy [207], or to monotherapy. The rationale of de-escalation is to avoid broad-spectrum antibiotics whenever possible, diminishing selection pressure and ultimately the prevalence of MDR bacteria, but the practice is controversial as data are scant [208]. The data are strongest for patients with VAP, with higher survival rates reported in several studies [209, 210], obtaining sputum samples before antibiotic administration is a crucial facet to make de-escalation possible. De-escalation has been embraced as part of ASP.

The MIC, the lowest antimicrobial agent concentration that inhibits microbial growth, can be determined by different methods, such as broth or agar dilution, and disk or gradient diffusion. The MIC value, expressed as mcg/mL, is often translated by clinical microbiology laboratories as “susceptible,” “intermediate,” or “resistant” according to defined “breakpoints” established by the Clinical and Laboratory Standards Institute (CLSI, Wayne, PA, USA) or “susceptible,” “susceptible, increased exposure,” or “resistant” according to the criteria of the European Committee on Antimicrobial Susceptibility Testing (EUCAST, Vaxjo, Sweden) [34].

Rapid diagnostics may contribute in furtherance by limiting unnecessary initiation of broad-spectrum therapy, thus decreasing the need for subsequent de-escalation [211, 212]. Most of the commercially available rapid detection methods for MDR bacteria include genotyping that relies on the detection of resistance genes [213] based on DNA sequencing. Genotypic methods may be used in conjunction with phenotyping [214], but genotypic methods in current clinical use should be regarded as supplemental to traditional phenotypic antimicrobial susceptibility testing owing to several limitations. Genotyping can effectively predict AMR, but does not inform susceptibility testing. In addition, the panel of resistance determinants is small, so other resistance determinants

may not be detected. Moreover, with genotypic methods there is also the possibility of overestimating AMR, because the presence of a resistance gene is not necessarily associated with the phenotypic expression of resistance (the gene could be inactivated or not expressed).

The greatest advantage of genotyping is undoubtedly speed, with turnaround times of 1–4 h. Employment of comparative genomics, probes, microarrays, nucleic acid amplification techniques, and deoxyribonucleic acid sequencing should allow for the detection of multiple resistance genes or variants simultaneously. However, a logistic challenge in practice is that when new antibiotics are marketed, there may be a lag before methods to measure in vitro susceptibility are validated for clinical use, which may limit the initial clinical use of new agents [215].

Rapid diagnostic testing for possible pathogens is considered indispensable for ASPs. Coupled with prompt, appropriate therapy, antibiotic use is decreased, mortality is reduced, hospital stays are shortened, and cost is lowered [216–218]. The lack of availability of modern diagnostic tests represents an important barrier in low-resource settings [219].

Using the shortest duration of antibiotics based on evidence

The duration of antibiotic therapy prescribed in daily practice is often longer than recommended by guidelines [220]. WHO [220] recommends against prolonging the administration of SAP after surgical intervention to prevent SSIs, based on a meta-analysis [220] of 69 randomized controlled trials (RCTs) investigating the optimal duration of SAP. For clean and clean-contaminated procedures, CDC guidelines recommend not to give additional doses of prophylactic antibiotics after the surgical incision has been closed in the operating room, even in the presence of a drain [109]. Updated guidelines of IDSA and SHEA recommend stopping all SAP at incision closure, regardless of procedure type or duration [221].

de Jonge et al. examined the effect of continued SAP on the rate of SSI [222]. Eighty-three RCTs were evaluated; 52 (19,273 participants) were included in the primary meta-analysis. No conclusive evidence for the benefit of the post-operative continuation of antibiotic prophylaxis (vs. discontinuation) was identified. When combined with a comprehensive approach to best practices in SSI prevention, post-operative continuation of SAP produced no additional benefit in reducing the incidence of SSI in any surgical setting. In a 2019 multicenter retrospective cohort study [223], increased duration of antibiotic prophylaxis was associated with a higher risk of acute kidney injury and CDI, but no reduction in SSIs.

A study of 34 urban and rural South African hospitals demonstrated that implementation of process improvement initiatives and principles targeted to institutional needs, utilizing pharmacists, effectively improved SAP guideline compliance and sustainable patient outcomes [224]. Efforts to shorten antibiotic therapy duration in hospital practice are a growing area of focus for ASPs [225]. However, Langford et al. showed that ASP advice to stop antibiotics or reduce their duration was accepted less often than advice to start or increase antibiotic exposure [226].

Shortening the duration of antibiotic therapy is a crucial tactic for reducing unnecessary inpatient antibiotic use, where antibiotic pressure is intense [227]. Although there are circumstances that may require prolonged antibiotic therapy (e.g., endocarditis, osteomyelitis), the duration of antibiotic therapy should always be as brief as possible. Regarding intra-abdominal infections, the STOP-IT trial [228] demonstrated that, in the setting of adequate source control, 4 days of antibiotic therapy was non-inferior to 8 days of therapy. In the DURAPOP randomized clinical trial [229], critically ill patients with post-operative intra-abdominal infections treated with a short course of antibiotics (8 days) showed similar outcomes compared with those treated for 15 days.

Antibiotic therapy of up to 21 days for VAP and hospital-acquired pneumonia (HAP) was used historically until several prospective studies demonstrated the effectiveness of shorter (7–8 days) therapy with no differences in mortality, intensive care unit (ICU) stay, mechanical ventilation-free days or organ failure-free days [230, 231]. The 2017 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines and the 2016 IDSA guidelines [232] both recommend 7 days of therapy for HAP/VAP. Ongoing studies [233] are determining if therapy duration could be reduced further.

Bacteremia caused by Enterobacterales has been treated traditionally with 2 weeks of antibiotics. Recent RCTs and meta-analyses investigating shorter (7–8 days) versus longer antibiotic courses (14–15 days) in patients with gram-negative bacteremia (mostly of urinary tract origin) demonstrate non-inferiority [234–239]. Regarding acute uncomplicated cellulitis, evidence also suggests that prolonged courses may be unnecessary and that 5 days of treatment may be sufficient [240]. IDSA guidelines recommend a 5-day antibiotic therapy duration for uncomplicated cellulitis, but may be extended if the infection has not improved within that time frame [241].

Generally, in critically ill patients, decisions about antibiotic therapy duration should be individualized, taking into account patient parameters such as severity of illness, the site and type of infection, whether source control has been achieved, whether PK has been optimized,

and clinical response [242]. Procalcitonin (PCT) may be useful to guide antibiotic therapy in the ICU. PCT-guided treatment can reduce the duration of therapy and length of hospital stay in adult critically ill patients with sepsis [243, 244]. Based on apparent benefit and no obvious undesirable effects, the 2021 Surviving Sepsis Campaign guidelines suggest using PCT along with a clinical evaluation to decide when to discontinue antibiotics in adults with an initial diagnosis of sepsis or septic shock and adequate source control, if the optimal duration of therapy is unclear and if PCT is available [183].

Achieving source control by identifying and eliminating the source of the infection or reducing the bacterial load

Source control aims to eliminate the source of infection, reduce the bacterial inoculum, and correct anatomic derangements to restore physiologic homeostasis. Additionally, it involves draining abscesses or infected fluid collections, debriding necrotic tissue, or removing contaminated medical devices, all being situations where antibiotics alone have limited efficacy.

Source control is crucial in the management of surgical infections, particularly intra-abdominal and soft tissue infections. Adequate source control achieved by the index operation allows for a shorter course of antibiotic therapy, thereby improving patients' outcomes, including lower risk of organ dysfunction [245, 246]. In the setting of uncomplicated intra-abdominal infections, such as uncomplicated appendicitis or cholecystitis, post-operative antibiotic therapy is not necessary if source control is adequate [246]. In the setting of complicated intra-abdominal infections, a short course of antibiotic therapy is always suggested even if source control is adequate [228, 229].

In some circumstances, organizational determinants may influence the excessive use of antibiotics. For example, acute cholecystitis should be managed by early cholecystectomy [247]. Nevertheless, because operating room availability is at a premium in many centers, acute cholecystitis cases are sometimes managed by percutaneous drainage or a delayed cholecystectomy, requiring a longer duration of antibiotic therapy.

The urgency (but not the need, ultimately) for source control is determined by the affected organ(s) and the rapidity at which underlying physiological stability deteriorates. Prompt source control may also be important for indolent infections (e.g., infected medical devices). A challenging management problem is central venous catheters associated with catheter-related blood stream infections. In these cases, removal of the catheter (required if the pathogen is *Pseudomonas* spp., *S. aureus* or fungal) constitutes source control. There is little reason to delay source control, even for a few hours, in

patients with sepsis [248–250]. The 2021 Surviving Sepsis Campaign guidelines [183] recommend identifying the anatomic source of infection and implementing source control (if amenable) as soon as possible. Delays of as little as 6 h in the setting of sepsis or septic shock have been associated with increased mortality. A multicenter cohort study (2013–2017) of hospitalized adults with community-acquired sepsis (according to SEPSIS-3 definitions) undergoing source control procedures [251] showed that source control within 6 h was associated with a reduced risk of 90-day mortality. In a post hoc analysis of a multicenter observational study (Abdominal Sepsis Study, AbSeS) [252], urgent, successful source control was associated with improved survival, whereas appropriateness of empiric antibiotic treatment was not, suggesting that source control is determinative of outcome for patients with sepsis of abdominal origin. Prompt source control may also be important for other infections [253]. A prospective international cohort study of adult patients (≥ 18 years old) with hospital-acquired blood stream infections treated in ICUs (June 2019–February 2021) reported mortality of 37%. Failure to achieve source control, if required, was associated with death in a multivariable logistic regression model.

Some patients are prone to persistent or recurrent sepsis, despite initial attempts at source control [254]. Index source control procedures may fail up to 25% of the time in abdominal sepsis with shock [255]. Timely surgical re-intervention provides the only option that significantly improves outcomes. Failure of source control may be caused by incomplete initial source control, particularly if contamination is ongoing [256]. Failure of source control can be difficult to diagnose. Therefore, monitoring the success of source control is crucial, with a high index of suspicion if a patient does not improve. Most often, diagnosis is based on a lack of clinical improvement (persistent signs and symptoms of inflammation) and confirmed by imaging.

Supporting surveillance of HAIs and AMR, monitoring of antibiotic use, consumption, and the quality of prescribing

Surveillance and prevalence studies to determine the frequency of HAIs are crucial tactics of a strategy to reduce HAIs and contain AMR. Data on HAI prevalence allow hospitals to measure the effectiveness of IPC activities; audits and feedback are used to drive change, improving quality and safety. The European Healthcare-Associated Infections Surveillance Network (HAI-Net) [257], coordinated by the ECDC, provides surveillance of HAIs. The main priorities of HAI-Net are the coordination of European point prevalence surveys of HAIs and antimicrobial use in acute care hospitals and long-term care facilities, surveillance of SSIs, and

surveillance of HAIs in ICUs. In the USA, the CDC National Healthcare Safety Network (NHSN) [258] is the most widely used HAI tracking system. NHSN provides facilities and governmental entities with data needed to identify problem areas, measure progress of prevention efforts, and ultimately eliminate HAIs. In addition, NHSN allows tracking of blood transfusion safety errors and important healthcare process measures such as personnel influenza vaccination status, and IPC adherence rates. Surveillance of MDR bacteria provides a basis for taking action to control AMR. Consistent data on the incidence and prevalence of MDR bacteria and geographic patterns related to AMR guide patient treatment and monitor the effectiveness of interventions.

A recent joint publication by ECDC and the WHO Regional Office for Europe reported AMR rates in Europe, using data from invasive bacterial isolates [259]. Carbapenem resistance in *K. pneumoniae* and vancomycin resistance in *E. faecium* increased during 2016–2020. Moreover, high rates of resistance to third-generation cephalosporins and high rates of carbapenem-resistant *Acinetobacter* spp. and *P. aeruginosa* in several European Region countries were identified.

In 2015, WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS), a collaborative effort to standardize AMR surveillance worldwide. Since its launch, GLASS has expanded its coverage and as of 2021, 109 countries and territories worldwide have contributed data to GLASS [260]. High rates of AMR to first-line antibiotics were reported by most countries and in some countries even to last-resort antibiotics. GLASS data demonstrate that globally, carbapenem-resistant bacteria are a serious concern. High rates of carbapenem-resistant *Acinetobacter* spp. and *K. pneumoniae*, resistance to third-generation cephalosporins in Enterobacterales, MDR and XDR tuberculosis, and MRSA will require ongoing close monitoring.

Inappropriate antibiotic use is a main driver of AMR [261]. Data on antibiotic utilization (volume and appropriateness) are essential to evaluate the impact of ASPs. Antibiotic consumption and appropriateness of use can be measured at different levels from nationally down to the prescriber level, allowing informed, focused efforts to reduce unnecessary or inappropriate use [262]. The most common metric to monitor antibiotic consumption is based on the concept of the defined daily dose (DDD). The DDD is the average maintenance dose per day of an antibiotic used in adults for its primary indication. Expressing antibiotic consumption in DDD/1000 patient-days allows comparison regardless of differences in individual antibiotic choices, measuring changes over time to assess the impact of ASP interventions. Between

2000 and 2015, antibiotic consumption expressed in DDD increased by 65% from 21.1 to 34.8 billion DDDs, while the antibiotic consumption rate increased by 39%, from 11.3 to 15.7 DDD/1,000 inhabitants/day) in 76 countries worldwide [263]. Of particular concern was the rapid increase in the use of last-resort compounds, both in high-income countries and LMICs, such as glycolylglycyls, oxazolidinones, carbapenems, and polymyxins.

Educating staff and improving awareness

One of the goals of the WHO Global Action Plan on Antimicrobial Resistance [49] is to improve awareness and understanding of AMR through effective communication, education, and training. To address AMR, all prescribers must become stewards of antibiotics by prescribing appropriately and educating colleagues and patients on their proper use. The goal of raising awareness is to change behaviors that fuel AMR. Not only can behaviors, beliefs, and practices regarding antibiotic use be inappropriate, there are misconceptions about the concept of AMR itself and its emergence, dissemination, and impact. Clinical leaders should promote awareness by encouraging an institutional culture of patient safety and responsible use where clinicians are persuaded, rather than constrained, to be compliant with antibiotic prescribing measures. Strong patient safety cultures promote education, collaboration, and engagement. Patients must also be engaged with information about the social cost of AMR and the individual benefits of targeted therapy.

The ultimate goal of any stewardship program should be to stimulate a behavioral change in prescribing practices [264]. It is important to incorporate fundamental antimicrobial stewardship, diagnostic stewardship, and IPC principles in under- and post-graduate training and education in order to provide confidence, skills, and expertise in the field of infection management [265]. The education of prescribers is pivotal to convince clinicians to use antibiotics appropriately [1], by respecting correct prescribing practices and following IPC recommendations. There is an urgent call for the integration of antimicrobial stewardship teaching at the undergraduate level of medical education to train future prescribers on this critical aspect of public health. Proper undergraduate education on rational antibiotics use would enable health professional graduates to enter clinical practice with adequate competencies to become rational prescribers [266]. However, although education to intensify AMR prevention is fundamental, without concurrent interventions education alone is of little value. Diagnostic uncertainty, fear of clinical failure or potential litigation, time pressure, or organizational contexts can complicate antibiotic prescribing decisions.

A cross-sectional study of perceptions and practices of physicians and pharmacists regarding antibiotic misuse at primary care centers in the Middle East reported a number of misconceptions and inappropriate practices relating to antibiotic use in Qatar by patients and healthcare providers [267].

Interestingly, the study found that about a third (29.2%) of physicians felt they were often under pressure by patients to prescribe antibiotics. Physicians who are overworked, underinformed, or pressured tend to overprescribe antibiotics and thereby contribute to the spread of AMR. Patients often expect to be prescribed antibiotics, and this pressure can be difficult for physicians to ignore. However, physicians' communication with patients influences their satisfaction more than the actual receipt of antibiotics, especially when patients are asked by their physician to contact them if symptoms do not improve [268]. Therefore, these findings suggest that educating patients about their diagnosis and course of treatment may result in reduced demand for unwarranted antibiotics [267].

Supporting multidisciplinary ASPs and enhancing collaboration of healthcare professionals from various disciplines

The promotion of ASPs is pivotal to ensure more standardized and responsible antibiotic use within a healthcare facility [269]. ASPs promulgate and implement best practices to prescribe, administer, monitor, and dispose of antibiotics. However, practices for implementing ASPs may vary based on local culture, policies, and resources. Some hospitals still lack formal ASPs, but even established programs can struggle with sufficient resources and gaining acceptance [270]. The effectiveness of measures to reduce excessive antibiotic prescribing to hospital inpatients and the impact of these measures on reducing the incidence of AMR or CDI have been evaluated [271]. Analyzed measures were able to reduce AMR and HAIs and improve clinical outcomes. Restrictive interventions were recommended when the need to intervene is considered urgent, but over the long term (6 months or more), persuasive measures are equally effective [271].

Promoting ASPs across clinical specialties is crucial to ensuring standardized, rational antibiotic use within a facility as well as a healthcare system [272]. Collaboration allows sharing of knowledge and widespread diffusion of best practices. Timely and accurate reporting of susceptibility test results allows the selection of appropriate targeted therapy and may help reduce broad-spectrum antimicrobial use. ASPs can provide periodic reports on AMR and identify the local microbiological epidemiology

for both phenotypic and genotypic analyses [273]. This can impact greatly the choice of empiric therapy. When involved in an ASP, clinical prescribers with knowledge of infectious diseases may help refine antibiotic policy based on local data, audit antibiotic prescribing, provide feedback, integrate best practices of antibiotic use, and act as “champions” among colleagues. Such a champion model has been applied previously to surgical safety implementations in general, such as surgical checklists, and plays a key role in successful quality improvement at the hospital level [274].

Surgeons are responsible for many of the processes that impact the risk for SSIs and play a key role in their prevention. Surgeons are also at the forefront in managing patients with infections, often providing prompt source control and appropriate antibiotic therapy, and are directly responsible for their outcomes. In this context, the direct involvement of surgeons is of utmost importance [270].

Infections are the main factor contributing to ICU mortality. Intensivists have a crucial role in preventing and treating AMR in critically ill patients. Intensivists prescribe antimicrobial agents to challenging patients and thus are at the forefront of successful ASPs [275]. Emergency Departments (EDs) represent a particularly

important setting for addressing inappropriate antimicrobial prescribing practices, given the frequent use of antibiotics in this interface between the community and the hospital. Therefore, ED practitioners should also be involved in ASPs [276, 277]. An essential participant in ASPs, often unrecognized and underutilized, is the staff nurse. Nurses are first-responders, crucial communicators, and 24-h guardians of patient status [278]. Their role is becoming formalized in implementing and operating ASPs [278], performing numerous functions that are integral to success. Without adequate support and resources from healthcare administrators, the ASP will not function optimally, in that these programs do not generate revenue. The engagement of healthcare administrators has been confirmed as a key factor for both developing and sustaining an ASP [270].

Successful ASPs can reduce the incidence of infections and colonization with MDR bacteria, including CDI among inpatients [15]. The best means to improve ASP programs is to create a collaborative environment, including all prescribing practitioners [86, 270], to exchange knowledge on best practices and diagnostic capacity.

Due to the challenges posed by the development of new antibiotics, the emergence of MDR bacteria is likely to outpace the introduction of new drugs to combat



Fig. 14 Supporting a cohesive and multidisciplinary approach

them. Thus, it may be important to focus on alternative non-antibiotic measures to address AMR [279]. Health information technology is a novel approach to optimize antibiotic use in the healthcare setting, although computerized decision support for hospital antibiotic use may not work in all settings [280]. Curtis et al. demonstrated the utility of computerized decision support of antibiotic usage and even in reduction of mortality in hospital settings [281].

Whereas clinical research should work toward developing new management techniques and therapies to address AMR, physicians should continue to preserve the use of antibiotics as much as possible. Additionally, public health campaigns aimed at promoting awareness about the responsible use of antibiotics and IPC measures can also be crucial in reducing the spread of MDR bacteria.

This document confirms the mission of the Global Alliance for Infections in Surgery, promoting standards of care in managing surgical infections through a cohesive and multidisciplinary approach. The axiom “if you want to go fast, go alone; if you want to go far, go together” reminds us that we need global solidarity not only to reduce health inequalities, but also to be united against all global health challenges, including AMR (Fig. 14).

Conclusions

Appropriate use of antibiotics should be integral to good clinical practice and standards of care. Inappropriate antibiotic use as well as poor IPC practices are contributing to the development and spread of AMR. Antibiotics should be treated as a global public good on the verge of scarcity; there is a global collective responsibility to preserve them in order to avoid countless future victims of MDR infections. Infections, especially those with MDR bacteria, compromise the success of all medical practitioners, including surgeons. A technically proficient surgery will be unsuccessful if the patient succumbs to a HAI that cannot be treated. Through collaborative initiatives and a united front, a future of effective antimicrobial therapy can be envisioned for generations to come.

Abbreviations

AMR	Antimicrobial resistance
ASPs	Antimicrobial Stewardship Programs
CDC	Centers for Disease Control and Prevention
CDI	<i>Clostridioides difficile</i> infection
COVID-19	Coronavirus disease 2019
CRAB	Carbapenem-resistant <i>Acinetobacter baumannii</i>
CRE	Carbapenem-resistant enterobacterales
CRPA	Carbapenem-resistant <i>Pseudomonas aeruginosa</i>
DDD	Defined daily doses
ECDC	European Centre for Disease Prevention and Control
EDs	Emergency departments
GLASS	Global antimicrobial resistance and use surveillance system
HAIs	Hospital-acquired infections

HAP	Hospital-acquired pneumonia
HCWs	Healthcare workers
Hib	<i>Haemophilus influenzae</i> type B
ICU	Intensive care unit
IDSA	Infectious Diseases Society of America
IPC	Infection prevention and control
LMICs	Low- and middle-income countries
MDR	Multidrug-resistant
MIC	Minimal inhibitory concentration
MRSA	Methicillin-resistant <i>Staphylococcus aureus</i>
NAPs	National action plans
PCT	Procalcitonin
PD	Pharmacodynamics
PDR	Pan-drug-resistant
PK	Pharmacokinetics
RCTs	Randomized controlled trials
SAP	Surgical antibiotic prophylaxis
SARS-CoV-2	Severe acute respiratory syndrome coronavirus-2
SHEA	Society for Healthcare Epidemiology of America
SSIs	Surgical site infections
VAP	Ventilator-associated pneumonia
WHO	World Health Organization
XDR	Extensively drug-resistant

Acknowledgements

Worldwide Antimicrobial Resistance National/International Network Group (WARNING) Collaborators: Massimo Sartelli¹, Philip S. Barie², Federico Coccolini³, Mohamed Abbas⁴, Lilian M. Abbo^{5,6}, Gulnora K. Abdukhalilova⁷, Yishak Abraham⁸, Salisu Abubakar⁹, Fikri M. Abu-Zidan¹⁰, Yusuff Adebayo Adebisi^{11,12}, Harissou Adamou¹³, Gulara Afandiyeva¹⁴, Ervis Agastra¹⁵, Wadha A. Alfouzan^{16,17}, Majdi N. Al-Hasan¹⁸, Sajjad Ali¹⁹, Syed Muhammad Ali^{20,21}, Fatima Allaw²², Gbemisola Allwell-Brown²³, Afireenish Amir²⁴, Obed Kwabena Offe Amponsah²⁵, Abdelkarim Al Omari²⁶, Luca Ansaloni²⁷, Shamshul Ansari²⁸, Ana Belen Arauz²⁹, Goran Augustin^{30,31}, Bih Awazi³², Mohammad Azfar³³, Mamadou Saliou Bailo Bah³⁴, Miklosh Bala³⁵, Anura S.K. Banagala³⁶, Suman Baral³⁷, Matteo Bassetti^{38,39}, Luis Bavestrello⁴⁰, Gregory Beilman⁴¹, Kebebe Bekele⁴², Moussa Benboubker⁴³, Bojana Beovic^{44,45}, Maria Daniela Bergamasco⁴⁶, Silvia Bertagnolio⁴⁷, Walter L. Biffi⁴⁸, Stijn Blot^{49,50}, Marja A. Boermeester⁵¹, Robert A. Bonomo^{52,53}, Adrian Brink⁵⁴, Silvio Brusaferro⁵⁵, Jonathan Butemba⁵⁶, Miguel A. Cainzos⁵⁷, Adrian Camacho-Ortiz⁵⁸, Rafael Canton⁵⁹⁻⁶⁰, Antonio Cascio^{61,62}, Alessandro Cassini^{63,64}, Enrique Castro-Sanchez⁶⁵⁻⁶⁷, Marco Catarci⁶⁸, Rodolfo Catena⁶⁹, Leili Chamani-Tabrizi⁷⁰, Sujith J. Chandry⁷¹, Esmita Charani⁷², William G. Cheadle⁷³, Diana Chebet⁷⁴, Ibrahim Chikowe⁷⁵, Francesca Chiara⁷⁶, Vincent Chi-Chung Cheng^{77,78}, Anna Chioti⁷⁹, Maria Elena Cocuz^{80,81}, Raul Coimbra⁸², Francesco Cortese⁸³, Yunfeng Cui⁸⁴, Jacek Czepiel^{85,86}, Mira Dasic⁸⁷, Nataliya de Francisco Serpa⁸⁸, Stijn W. de Jonge⁸⁹, Samir Delibegovic⁸⁹, E. Patchen Dellinger⁹⁰, Zaza Demetrasvili⁹¹, Alessandra De Palma⁹², Danushka De Silva⁹³, Belinda De Simone⁹⁴, Jan De Waele⁹⁵, Sameer Dhingra⁹⁶, Jose J. Diaz⁹⁷, Claudia Dima⁹⁸, Natalia Dirani⁹⁹, Cornelius C. Dodoo¹⁰⁰, Gereltuya Dorj^{101,102}, Therese M. Duane¹⁰³, Christian Eckmann¹⁰⁴, Beverly Egyir¹⁰⁵, Mutasim M. Elmangory¹⁰⁶, Mushira A. Enani¹⁰⁷, Onder Ergonul^{108,09}, Juan Pablo Escalera-Antezana¹¹⁰, Kevin Escandon¹¹¹, Abdul-Wahab Omo-ope Ettu^{112,113}, Joseph O. Fadare¹¹⁴, Massimo Fantoni¹¹⁵, Mohammad Farahbakhsh¹¹⁶, Mario Paulo Faro¹¹⁷, Alberto Ferreres¹¹⁸, Gianina Flocco¹¹⁹, Esteban Foianini¹²⁰, Donald E. Fry¹²¹, Alberto Federico Garcia^{122,123}, Chiara Gerardi¹²⁴, Wagih Ghannam¹²⁵, Helen Giamarellou¹²⁶, Natalya Glushkova¹²⁷, George Gkiokas¹²⁸, Debra A. Goff¹²⁹, Harumi Gomi¹³⁰, Magnus Gottfredsson^{131,132}, Ewen A. Griffiths¹³³, Rosio Isabel Guerra Gronerth^{134,135}, Xavier Guirao¹³⁶, Yogesh K. Gupta¹³⁷, Gregory Halle-Ekane¹³⁸, Sonja Hansen¹³⁹, Mainul Haque¹⁴⁰, Timothy C. Hardcastle¹⁴¹, David T.S. Hayman¹⁴², Andreas Hecker¹⁴³, Markus Hell¹⁴⁴, Vanessa P. Ho^{145,146}, Adrien M. Hodonou¹⁴⁷, Arda Isik¹⁴⁸, Salequi Islam^{149,150}, Kamal M.F. Itani¹⁵¹, Nadia Jaidane¹⁵², Ib Jammer¹⁵³, David R. Jenkins¹⁵⁴, Ibrahim Franklyn Kamara¹⁵⁵, Souha S. Kanj¹⁵⁶, Desmond Jumbam¹⁵⁶, Masoud Keikha¹⁵⁷, Ashish K. Khanna^{158,159}, Sahil Khanna¹⁶⁰, Gaetanjal Kapoor¹⁶¹, Garima Kapoor¹⁶², Samuel Kariuki¹⁶³, Faryal Khamis¹⁶⁴, Vladimir Khokha¹⁶⁵, Reuben Kiggundu¹⁶⁶, Ronald Kiguba¹⁶⁷, Hong Bin Kim¹⁶⁸, Peter K. Kim¹⁶⁹, Andrew W Kirkpatrick¹⁷⁰, Yoram Kluger¹⁷¹, Wen-Chien Ko^{172,173}, Kenneth Y.Y. Kok¹⁷⁴, Vihar Kotecha¹⁷⁵, Ibrahim Kouma¹⁷⁶, Bojan Kovacevic¹⁷⁷, Jehona Krasniqi¹⁷⁸, Marcela Krutova¹⁷⁹, Igor Kryvoruchko¹⁸⁰, Ravina Kullar¹⁸¹, Kwaku A. Labi¹⁸², Francesco M. Labricciosa¹⁸³, Sulaiman Lakoh¹⁸⁴, Botond

- Lakatos^{185,186}, Mary Ann D. Lansang¹⁸⁷, Ramanan Laxminarayan¹⁶¹, Young Ran Lee¹⁸⁸, Marc Leone¹⁸⁹, Ari Leppaniemi¹⁹⁰, Gabriel Levy Hara¹⁹¹, Andrey Litvin¹⁹², Varut Lohsiriwat¹⁹³, Gustavo M. Machain¹⁹⁴, Fawzi Mahomoodally¹⁹⁵, Ronald V. Maier¹⁹⁶, Md Anwarul Azim Majumder¹⁹⁷, Sydney Malama¹⁹⁸, Justen Manasa¹⁹⁹, Vikas Manchanda²⁰⁰, Ramiro Manzano-Nunez²⁰¹, Luis Martínez-Martínez^{202,203}, Ignacio Martín-Loeches²⁰⁴⁻²⁰⁷, Sanjay Marwah²⁰⁸, Emilio Maseda²⁰⁹, Maleda Mathewos²¹⁰, Ryan C. Maves²¹¹, Deborah McNamara^{212,213}, Ziad Memish²¹⁴⁻²¹⁶, Dominik Mertz^{217,218}, Shyam Kumar Mishra^{219,220}, Philippe Montravers²²¹, Maria Luisa Moro²²², Elias Mossialos²²³, Fabrizio Motta²²⁴, Steward Mudenda²²⁵, Patrick Mugabi²²⁶, Mc Juan Muco Mugisha²²⁶, Eleftherios Mylonakis^{227,228}, Lena M. Napolitano²²⁹, Dilip Nathwani²³⁰, Leontine Nkamba²³¹, Emmanuel Fru Nsubutebu²³², Donal B. O'Connor²³³, Sade Ogunsola²³⁴, Peter Østrup Jensen^{235,236}, Juliana Maria Ordoñez¹²², Carlos A. Ordoñez^{122,123}, Pablo Ottolino²³⁷, Abdoul-Salam Ouedraogo^{238,239}, José Artur Paiva^{240,241}, Miriam Palmieri²⁴², Angelo Pan²⁴³, Narayan Pant^{244,245}, Arpad Panyko²⁴⁶, Ciro Paolillo²⁴⁷, Jay Patel^{248,249}, Federico Pea^{250,251}, Patrizio Petrone²⁵², Nicola Petrosillo²⁵³, Tadeja Pintar²⁵⁴, Haralds Plaudis^{255,256}, Mauro Podda²⁵⁷, Alfredo Ponce-de-Leon²⁵⁸, Susan L. Powell²⁵⁹, Adrián Puello-Guerrero²⁶⁰, Celine Pulcini²⁶¹, Kemal Rasa²⁶², Jean-Marc Regimbeau²⁶³, Jordi Rello^{264,265}, Manuel Renato Retamozo-Palacios²⁶⁶, Glendee Reynolds-Campbell²⁶⁷, Julival Ribeiro²⁶⁸, Jennifer Rickard²⁶⁹, Nuno Rocha-Pereira²⁷⁰, Victor D. Rosenthal²⁷¹, Gian Maria Rossolini^{272,273}, Godfrey M. Rwegera²⁷⁴, Megan Rwigamba²⁷⁵, Michela Sabbatucci^{276,277}, Žilvinas Saladžinskas²⁷⁸, Rasha E. Salama²⁷⁹, Tondore Sai²⁸⁰, Samson Sahile Salile^{281,282}, Ibrahim Sal²⁸³, Hossein Samadi Kafil²⁸⁴, Boris E. Sakakushev²⁸⁵, Robert G. Sawyer²⁸⁶, Marco Scatizzi²⁸⁷, Jeremiah Seni²⁸⁸, Edward J. Septimus^{289,290}, Gabriele Sganga²⁹¹, Daniel Mønsted Shabanzadeh²⁹², Vishal G. Shelat^{293,294}, Agumas Shibabaw²⁹⁵, Francis Somville^{296,297}, Selma Souf²⁹⁸, Stefania Stefani²⁹⁹, Evelina Tacconelli³⁰⁰, Buon Kim Tan³⁰¹, Pierre Tattevin³⁰², Carlos Rodriguez-Taveras³⁰³, João Paulo Telles³⁰⁴, Orlando Téllez-Almenares³⁰⁵, Jeffrey Tessier³⁰⁶, Nguyen Toan Thang³⁰⁷, Cristian Timmermann³⁰⁸, Jean-François Timsit^{309,310}, Joel Noutakdie Tochie³¹¹, Matti Tolonen¹⁹⁰, Gabriel Trueba³¹², Constantinos Tsioutsis³¹³, Fabio Tumietto³¹⁴, Felipe Francisco Tuon³¹⁵, Jan Ulrych³¹⁶, Selman Uranues³¹⁷, Maarten van Dongen³¹⁸, Harry van Goor³¹⁹, George C. Velmahos³²⁰, Andras Vereczkei³²¹, Bruno Viaggi³²², Pierluigi Viale^{323,324}, Jordi Vila³²⁵⁻³²⁷, Andreas Voss³²⁸, Jasmina Vraneš^{329,330}, Richard R. Watkins³³¹, Nyambura Wanjiru-Korir³³², Olivia Waworuntu³³³, Agnes Wechsler-Fördös³³⁴, Klara Yadgarova³³⁵, Mohammed Yahaya³³⁶, Ali I Yahya³³⁷, Yonghong Xiao³³⁸, Andee Dzulkarnaen Zakaria³³⁹, Tanya L. Zakrisson³⁴⁰, Victor Zamora Mesa³⁴¹, Walter Siquini¹, Ara Darzi³⁴², Leonardo Pagani³⁴³, Fausto Catena³⁴⁴.
- ¹Department of Surgery, Macerata Hospital, Macerata, Italy. ²Department of Surgery, Weill Cornell Medicine, New York, New York, USA. ³General, Emergency and Trauma Surgery Unit, Pisa University Hospital, Pisa, Italy. ⁴Infection Control Program, University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland. ⁵Antimicrobial Stewardship Program, Department of Pharmacy, Jackson Health System, Miami, Florida, USA. ⁶Division of Infectious Diseases and Miami Transplant Institute, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA. ⁷Research Institute of Epidemiology, Microbiology and Infectious Diseases, Tashkent, Republic of Uzbekistan. ⁸Addis Ababa University, College of Health Sciences, Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT-Africa), Addis Ababa, Ethiopia. ⁹School of Health Sciences, University of Dundee, Dundee, UK. ¹⁰The Research Office, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates. ¹¹Nuffield Department of Population Health, University of Oxford, Oxford, UK. ¹²Global Health Focus, Kigali, Rwanda. ¹³Department of Surgery and Surgical Specialties, Zinder National Hospital, Faculty of Health Sciences, University of Zinder, Niger. ¹⁴Enhancing Primary Health Care Services Project, Representative Office of the Swiss Tropical and Public Health Institute, Dushanbe, Tajikistan. ¹⁵General Surgery Department, Regional Hospital of Korçe, Albania. ¹⁶Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait. ¹⁷Microbiology Unit, Department of Laboratories, Farwania Hospital, Farwania, Kuwait. ¹⁸Department of Internal Medicine, University of South Carolina School of Medicine, Columbia, South Carolina, USA. ¹⁹Department of Internal Medicine, Rehman Medical Institute, Peshawar, Pakistan. ²⁰Department of Surgery, Weill Cornell Medical College, Doha, Qatar. ²¹Acute Care Surgery, Hamad General Hospital, Doha, Qatar. ²²Infectious Diseases Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon. ²³Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden. ²⁴Department of Microbiology, National Institute of Health, Islamabad, Pakistan. ²⁵Department of Pharmacy Practice, Faculty of Pharmacy and Pharmaceutical Sciences, College of Health Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. ²⁶Department of General Surgery, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. ²⁷Department of General and Emergency Surgery, Fondazione IRCCS San Matteo, Pavia, Italy. ²⁸Faculty of Health Sciences, Abu Dhabi Women's College, Higher Colleges of Technology, Abu Dhabi, United Arab Emirates. ²⁹Infectious Diseases Department, Hospital Santo Tomas, Avenida Balboa, Panama City, Panama. ³⁰School of Medicine, University of Zagreb, Zagreb, Croatia. ³¹Department of Surgery, University Hospital Centre Zagreb, Zagreb, Croatia. ³²Medical Laboratory, Ekomdoun Baptist Hospital Yaounde, Yaounde, Cameroon. ³³Department of Surgery, Yas Clinic Hospital, Khalifa City, Abu Dhabi, United Arab Emirates. ³⁴Université Gamal Abdel Nasser, Conakry, Guinea. ³⁵Acute Care Surgery and Trauma Unit, Department of General Surgery, Hadassah Medical Center and Faculty of Medicine, Hebrew University of Jerusalem Kiriath Hadassah, Jerusalem, Israel. ³⁶Department of Surgery, National Hospital of Sri Lanka, Colombo, Sri Lanka. ³⁷Department of Surgery, Dirghayu Pokhara Hospital, Pokhara, Nepal. ³⁸Department of Health Sciences (DISSAL), University of Genoa, Genoa, Italy. ³⁹Unit of infectious diseases, IRCCS Ospedale Policlinico San Martino, Genoa, Italy. ⁴⁰Clinica Reñaca, Viña Del Mar, Chile. ⁴¹Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA. ⁴²Department of Surgery, Madda Walabu University Goba Referral Hospital, Bala-Robe, Ethiopia. ⁴³Human Pathology Biomedicine and Environment Laboratory, Faculty of Medicine and Pharmacy, Sidi Mohammed Ben Abdellah University, Fez, Morocco. ⁴⁴Department of Infectious Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia. ⁴⁵Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia. ⁴⁶Hospital do Coração, Sao Paulo, Brazil. ⁴⁷Department of Control, Surveillance and Prevention of Antimicrobial Resistance, World Health Organization, Geneva, Switzerland. ⁴⁸Division of Trauma and Acute Care Surgery, Scripps Clinic Medical Group, La Jolla, California, USA. ⁴⁹Department of Internal Medicine and Pediatrics, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium. ⁵⁰UQ Centre for Clinical Research, The University of Queensland, Brisbane, Australia. ⁵¹Department of Surgery, Amsterdam Gastroenterology and Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands. ⁵²Research Service, VA Northeast Ohio Healthcare System, Cleveland, Ohio, USA. ⁵³Case Western Reserve University-Cleveland VA Medical Center for Antimicrobial Resistance and Epidemiology (Case VA CARES), Cleveland, Ohio, USA. ⁵⁴Division of Medical Microbiology, Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. ⁵⁵Department of Medicine, University of Udine, Udine, Italy. ⁵⁶Gulu University, Faculty of Medicine, Global Surgery Unit, Laroo, Uganda. ⁵⁷Department of Surgery, Hospital Clínico Universitario, IDIS, University of Santiago de Compostela, Spain. ⁵⁸Department of Infectious Diseases, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ), Mexico City, Mexico. ⁵⁹Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. ⁶⁰CIBER en Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain. ⁶¹Infectious and Tropical Disease Unit, AOU Policlinico "P. Giaccone", Palermo, Italy. ⁶²Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties "G. D'Alessandro", University of Palermo, Palermo, Italy. ⁶³Cantonal Doctor Office, Public Health Department, Canton of Vaud, Lausanne, Switzerland. ⁶⁴Infection Prevention and Control Unit, Infectious Diseases Service, Lausanne University Hospital, Lausanne, Switzerland. ⁶⁵NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK. ⁶⁶College of Business, Arts, and Social Sciences, Brunel University, London, UK. ⁶⁷Global Health Group, University of Balearic Islands, Palma, Spain. ⁶⁸General Surgery Unit, Sandro Pertini Hospital, ASL Roma 2, Roma, Italy. ⁶⁹UCL Global Business School for Health, London, UK. ⁷⁰Infectious Diseases Unit, Clemenceau Medical Center Hospital, Dubai, United Arab Emirates. ⁷¹Department of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, India. ⁷²National Institute for Health Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK. ⁷³Department of Surgery, School of Medicine, University of Louisville, Louisville, KY, USA. ⁷⁴Kenyatta National Hospital, Nairobi, Kenya. ⁷⁵Pharmacy Department, Kamuzu University of Health Sciences (KUHS), Blantyre, Malawi. ⁷⁶Center for Infectious Disease Research and Policy, Antimicrobial Stewardship Project, University of Minnesota. Minneapolis, Minnesota, USA. ⁷⁷Department of Microbiology, Li Ka

- Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Semi-Autonomous Republic, China. ⁷⁸Department of Microbiology, Queen Mary Hospital, Hong Kong SAR, China. ⁷⁹Division of Pharmacy and Medicines, Luxembourg Health Directorate-Direction de la santé, Luxembourg, Grand Duchy of Luxembourg. ⁸⁰Clinical Hospital of Pneumophthisiology and Infectious Diseases, Brasov, Romania. ⁸¹Faculty of Medicine, Transylvania University of Brasov, Brasov, Romania. ⁸²Department of Surgery, Riverside University Health System Medical Center, Loma Linda University, Loma Linda, California, USA. ⁸³Emergency Surgery Unit, San Filippo Neri Hospital, Roma, Italy. ⁸⁴Department of Surgery, Tianjin Nankai Hospital, Nankai Clinical School of Medicine, Tianjin Medical University, Tianjin, China. ⁸⁵Department of Infectious Diseases, University Hospital in Krakow, Krakow, Poland. ⁸⁶Department of Infectious and Tropical Diseases, Jagiellonian University Medical College, Krakow, Poland. ⁸⁷South-Eastern Europe Health Network (SEEHN), Skopje, North Macedonia. ⁸⁸The World Bank, Washington, District of Columbia, USA. ⁸⁹Clinic for Surgery, University Clinical Centre of Tuzla, Bosnia and Herzegovina. ⁹⁰Department of Surgery, University of Washington, Seattle, Washington, USA. ⁹¹Department of Surgery, Tbilisi State Medical University, Tbilisi, Georgia. ⁹²Forensic Medicine and Integrated Risk Management Unit, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ⁹³Directorate of Healthcare Quality and Safety, Ministry of Health, Sri Jayawardenapura Kotte, Sri Lanka. ⁹⁴Digestive and Metabolic Minimally Invasive Surgery Unit, Clinique Saint Louis, Poissy, Poissy, Ile de France, France. ⁹⁵Department of Intensive Care Medicine, Ghent University Hospital, Ghent, Belgium. ⁹⁶Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research (NIPER), Hajipur, India. ⁹⁷Division of Acute Care Surgery, University of South Florida/Tampa General Hospital, Tampa, Florida, USA. ⁹⁸National Institute of Public Health, Bucharest, Romania. ⁹⁹Research Institute, McGill University Health Centre, Montreal, Canada. ¹⁰⁰School of Pharmacy, University of Health and Allied Sciences, Ho, Ghana. ¹⁰¹Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia, Adelaide, Australia. ¹⁰²Mongolian National University of Medical Sciences, Ulaanbaatar, Mongolia. ¹⁰³Department of Surgery, Medical City Plano, Plano, Texas, USA. ¹⁰⁴Department of General, Visceral and Thoracic Surgery, Klinikum Hann. Münden Academic Hospital of Goettingen University, Hann. Münden, Germany. ¹⁰⁵Department of Bacteriology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Legon, Ghana. ¹⁰⁶National Public Health Laboratory, Khartoum, Sudan. ¹⁰⁷Infectious Diseases Section, King Fahad Medical City, Riyadh, Saudi Arabia. ¹⁰⁸Department of Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey. ¹⁰⁹Koç University İşbank Center for Infectious Diseases, Koç University, Istanbul, Turkey. ¹¹⁰Direction of First Level, Municipal Secretary of Health, Municipal Autonomous Government of Cochabamba, Cochabamba, Bolivia. ¹¹¹Division of Infectious Diseases and International Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA. ¹¹²Lagos State Health Service Commission, Lagos, Nigeria. ¹¹³Department of Pathology, General Hospital Odan, Lagos, Nigeria. ¹¹⁴Department of Pharmacology and Therapeutics, College of Medicine, Ekiti State University, Ado-Ekiti, Nigeria. ¹¹⁵Dipartimento di Scienze di Laboratorio e Infettivologiche, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. ¹¹⁶Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. ¹¹⁷General and Trauma Surgery Division, Hospital das Clínicas, School of Medicine, São Paulo State University, Brazil. ¹¹⁸Department of Surgery, University of Buenos Aires, Buenos Aires, Argentina. ¹¹⁹Department of Gastroenterology and Hepatology, Cleveland Clinic, Cleveland, Ohio, USA. ¹²⁰Clínica Foianini, Santa Cruz de la Sierra, Santa Cruz, Bolivia. ¹²¹Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. ¹²²Division of Trauma and Acute Care Surgery, Department of Surgery, Department of Intensive Care, Fundación Valle del Lili, Cali, Colombia. ¹²³Division of Trauma and Acute Care Surgery, Department of Surgery, Universidad del Valle, Cali, Colombia. ¹²⁴Istituto di Ricerche Farmacologiche "Mario Negri" IRCCS, 20156 Milan, Italy. ¹²⁵Department of Surgery, Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt. ¹²⁶First Department of Internal Medicine-Infectious Diseases, Hygeia General Hospital, Athens, Greece. ¹²⁷Faculty of Medicine and Health Care, Al-Farabi Kazakh National University, Almaty, Kazakhstan. ¹²⁸Department of Surgery, Medical School, National and Kapodistrian University of Athens, "Aretaieio" Hospital, Athens, Greece. ¹²⁹Department of Pharmacy, The Ohio State University Wexner Medical Center, Ohio State University College of Pharmacy, Columbus, Ohio, USA. ¹³⁰Office of Medical Education and Center for Infectious Diseases, International University of Health and Welfare School of Medicine, Narita, Chiba, Japan. ¹³¹Department of Infectious Diseases, Landspítali University Hospital, Reykjavík, Iceland. ¹³²Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavík, Iceland. ¹³³Department of Upper Gastrointestinal Surgery, Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham NHS Trust, Birmingham, UK. ¹³⁴Centro Médico Naval Cirujano Mayor Santiago Távora, Callao, Peru. ¹³⁵School of Medicine, Universidad Científica del Sur, Lima, Peru. ¹³⁶Unit of Endocrine, Head, and Neck Surgery and Unit of Surgical Infections Support, Department of General Surgery, Parc Taulí Hospital Universitari, Sabadell, Spain. ¹³⁷Rukamni Birla hospital, Jaipur, India. ¹³⁸Faculty of Health Sciences, University of Buea, Buea, Cameroon. ¹³⁹Institute of Hygiene and Environmental Medicine, Charité-Universitätsmedizin Berlin, Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. ¹⁴⁰Unit of Pharmacology, Faculty of Medicine and Defence Health, Universiti Pertahanan Nasional Malaysia, Kuala Lumpur, Malaysia. ¹⁴¹Department of Surgical Sciences, Nelson R Mandela School of Clinical Medicine, University of KwaZulu-Natal, and Inkosi Albert Luthuli Central Hospital, Durban, South Africa. ¹⁴²Molecular Epidemiology and Public Health Laboratory, Hopkirk Research Institute, Massey University, Palmerston North, New Zealand. ¹⁴³Department of General and Thoracic Surgery, University Hospital of Giessen, Giessen, Germany. ¹⁴⁴Department of Clinical Microbiology and Hygiene, Medilab, Academic Teaching Laboratories of the Paracelsus Medical University, Salzburg, Austria. ¹⁴⁵Division of Trauma Surgery, Acute Care Surgery, Critical Care, and Burns, Department of Surgery, MetroHealth Medical Center, Cleveland, Ohio; Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. ¹⁴⁶Case Western Reserve University, Department of Population and Quantitative Health Sciences, Cleveland, Ohio, USA. ¹⁴⁷Department of Surgery, Faculty of Medicine, University of Parakou, Parakou, Benin. ¹⁴⁸Department of Surgery, Istanbul Medeniyet University, Türkiye. ¹⁴⁹School of Optometry and Vision Science, University of New South Wales, Sydney, Australia. ¹⁵⁰Department of Microbiology, Jahangirnagar University, Savar, Dhaka, Bangladesh. ¹⁵¹Department of Surgery, Veterans Affairs Boston Health Care System, Boston University Chobanian and Avedisian School of Medicine, and Harvard Medical School, Boston, Massachusetts, USA. ¹⁵²Research Unit, Emergent Bacterial Resistance and Safety of Care UR12SP37, Laboratory of Microbiology, University Hospital Sahloul, Sousse, Tunisia. ¹⁵³Department of Anesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway. ¹⁵⁴Department of Clinical Microbiology, University Hospitals of Leicester NHS Trust, Leicester, UK. ¹⁵⁵World Health Organization Country Office, Freetown, Sierra Leone. ¹⁵⁶Department of Health Policy and Advocacy, Operation Smile, Virginia Beach, Virginia, USA. ¹⁵⁷Department of Microbiology and Virology, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran. ¹⁵⁸Department of Anesthesiology, Section on Critical Care Medicine, Wake Forest Center for Biomedical Informatics, Perioperative Outcomes and Informatics Collaborative, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. ¹⁵⁹Outcomes Research Consortium, Cleveland, Ohio, USA. ¹⁶⁰Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA. ¹⁶¹One Health Trust, Washington, District of Columbia, USA. ¹⁶²Department of Microbiology, Gandhi Medical College, Bhopal, India. ¹⁶³Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya. ¹⁶⁴Adult Infectious Diseases, Department of Medicine, Royal Hospital, Muscat, Oman. ¹⁶⁵Department of Emergency Surgery, City Hospital, Mozyr, Belarus. ¹⁶⁶USAID Medicines, Technologies, and Pharmaceutical Services Program, Management Sciences for Health, Kampala, Uganda. ¹⁶⁷Department of Pharmacology and Therapeutics, College of Health Sciences, Makerere University, Kampala, Uganda. ¹⁶⁸Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. ¹⁶⁹Department of Surgery, Jacobi Medical Center, Albert Einstein College of Medicine, New York, New York, USA. ¹⁷⁰Departments of Surgery and Critical Care Medicine, University of Calgary, Foothills Medical Centre, Calgary, AB, Canada. ¹⁷¹Department of General Surgery, Rambam Medical Center, Haifa, Israel. ¹⁷²Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. ¹⁷³Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. ¹⁷⁴Pengiran Anak Puteri Rashidah Sa'adatulk Bolkiah Institute of Health Sciences, Universiti Brunei Darussalam, Bandar Seri Begawan, Brunei. ¹⁷⁵Department of General Surgery, Catholic University of Health and Allied Sciences, Bugando, Mwanza, Tanzania. ¹⁷⁶One Health in Action Initiative, Bouaké, Ivory Coast. ¹⁷⁷Department of Surgery, UMC Zvezdara, Belgrade, Serbia. ¹⁷⁸Clinic of Infectious Diseases, University Clinical

- Center of Kosova, Prishtina, Kosovo. ¹⁷⁹Department of Medical Microbiology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic. ¹⁸⁰Department of Surgery No.2, Kharkiv National Medical University, Kharkiv, Ukraine. ¹⁸¹Expert Stewardship, Inc., Newport Beach, California, USA. ¹⁸²Department of Medical Microbiology, University of Ghana Medical School, Accra, Ghana. ¹⁸³Global Alliance for Infections in Surgery, Macerata, Italy. ¹⁸⁴Department of Internal Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Sierra Leone. ¹⁸⁵South Pest Central Hospital, National Institute of Hematology and Infectious Diseases, Budapest, Hungary. ¹⁸⁶Department of Internal Medicine and Hematology, Division of Infectology, Semmelweis University, Budapest, Hungary. ¹⁸⁷Department of Clinical Epidemiology, University of the Philippines, Manila, Philippines. ¹⁸⁸Department of Clinical Sciences, Ben and Maytee Fisch College of Pharmacy, University of Texas at Tyler, TX, USA. ¹⁸⁹Department of Anaesthesia and Intensive Care Unit, Aix-Marseille University, AP-HM, North Hospital, Marseille, France. ¹⁹⁰Department of Abdominal Surgery, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. ¹⁹¹Unit of Infectious Diseases, Hospital Carlos G. Durand, Buenos Aires, Argentina. ¹⁹²Department of Surgery, Immanuel Kant Baltic Federal University, Kaliningrad, Russia. ¹⁹³Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. ¹⁹⁴Department of Surgery, Universidad Nacional de Asuncion, Asuncion, Paraguay. ¹⁹⁵Department of Health Sciences, Faculty of Medicine and Health Sciences, University of Mauritius, Réduit, Mauritius. ¹⁹⁶Department of Surgery, Harborview Medical Center, University of Washington, Seattle, Washington, USA. ¹⁹⁷Faculty of Medical Sciences, The University of the West Indies, Cave Hill Campus, Bridgetown, Barbados. ¹⁹⁸Department of Biological Sciences, School of Natural Sciences, University of Zambia, Lusaka, Zambia. ¹⁹⁹Microbiology Unit, Faculty of Medicine and Health Sciences, University of Zimbabwe, Harare, Zimbabwe. ²⁰⁰Department of Microbiology, Maulana Azad Medical College, New Delhi, India. ²⁰¹Clinical Research Unit, Hospital del Mar Medical Research Institute, Barcelona, Spain. ²⁰²Unit of Microbiology, University Hospital Reina Sofia, Córdoba, Spain. ²⁰³Department of Agricultural Chemistry, Edaphology and Microbiology, Maimonides Biomedical Research Institute of Cordoba, Córdoba, Spain. ²⁰⁴Department of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organisation, St James's Hospital, Dublin, Ireland. ²⁰⁵Trinity College Dublin, Dublin, Ireland. ²⁰⁶Centro de Investigación Biomedica En Red Enfermedades Respiratorias, Institute of Health Carlos III, Madrid, Spain. ²⁰⁷Pulmonary Department, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain. ²⁰⁸Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, India. ²⁰⁹Department of Anesthesiology and Surgical Critical Care, Hospital Universitario La Paz, Madrid, Spain. ²¹⁰Department of Surgery, Wolaia Sodo University, Sodo, Ethiopia. ²¹¹Section of Infectious Diseases, Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA. ²¹²Department of Colorectal Surgery, Beaumont Hospital, Dublin, Ireland. ²¹³Royal College of Surgeons, St. Stephen's Green, Dublin, Ireland. ²¹⁴Al-Faisal University, Riyadh, Saudi Arabia. ²¹⁵Ministry of Health, King Saud Medical City, Riyadh, Saudi Arabia. ²¹⁶Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA. ²¹⁷Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada. ²¹⁸Department of Medicine, McMaster University, Hamilton, Ontario, Canada. ²¹⁹Department of Microbiology, Tribhuvan University Teaching Hospital, Institute of Medicine, Kathmandu, Nepal. ²²⁰School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia. ²²¹Département d'anesthésie-réanimation, université de Paris, CHU Bichat-Claude Bernard, APHP, Paris, France. ²²²Italian Multidisciplinary Society for the Prevention of Healthcare-associated infections, Milan, Italy. ²²³Department of Health Policy, London School of Economics and Political Science, London, UK. ²²⁴Hospital da Criança Santo Antônio, Porto Alegre, Brazil. ²²⁵Department of Pharmacy, School of Health Sciences, University of Zambia, Lusaka, Zambia. ²²⁶Rinda Ubuzima Clinical Research Center, Kigali, Rwanda. ²²⁷Department of Medicine, Houston Methodist Hospital and Academic Institute, Houston, Texas, USA. ²²⁸Weill Cornell Medicine, New York, NY, USA. ²²⁹Department of Surgery, University of Michigan Health System, Ann Arbor, Michigan, USA. ²³⁰Global Antimicrobial Stewardship Partnership Hub, British Society for Antimicrobial Chemotherapy, Birmingham, UK. ²³¹Higher Teacher Training College, University of Bertoua, Cameroon. ²³²Tropical and Infectious Diseases Division, Sheikh Shakhboub Medical City, Abu Dhabi, United Arab Emirates. ²³³Department of Surgery, School of Medicine, Trinity College, Dublin, Ireland. ²³⁴Centre for Integrated Health Programs, Lagos University Teaching Hospital, Lagos, Nigeria. ²³⁵Department of Clinical Microbiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ²³⁶Costerton Biofilm Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. ²³⁷Department of Surgery, Hospital Sotero Del Rio, Universidad Católica, Santiago, Chile. ²³⁸Emerging and Re-emerging Pathogens Laboratory, Sourô Sanou University Hospital Center, Bobo-Dioulasso, Burkina Faso. ²³⁹Bacteriology-Virology Department, Sourô Sanou University Hospital, Bobo-Dioulasso, Burkina Faso. ²⁴⁰Intensive Care Department, Centro Hospitalar Universitário São João, Porto, Portugal. ²⁴¹Department of Medicine, Faculty of Medicine, University of Porto, Portugal. ²⁴²Department of General and Emergency Surgery, Polytechnic University of Marche, Ancona, Italy. ²⁴³Unit of Infectious Diseases, ASST Cremona, Cremona, Italy. ²⁴⁴College of Medicine and Dentistry, James Cook University, Townsville, Australia. ²⁴⁵Australian Institute of Tropical Health and Medicine, Townsville, Australia. ²⁴⁶Fourth Department of Surgery, Faculty of Medicine, Comenius University Bratislava and University Hospital Bratislava, Slovakia. ²⁴⁷Emergency Department, University of Verona, Verona, Italy. ²⁴⁸Global Health Governance Program, Usher Institute, University of Edinburgh, Edinburgh, UK. ²⁴⁹School of Dentistry, Faculty of Medicine and Health, University of Leeds, Leeds, UK. ²⁵⁰Department of Medical and Surgical Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy. ²⁵¹Clinical Pharmacology Unit, Department for Integrated Infectious Risk Management, Azienda Ospedaliero-University di Bologna, Bologna, Italy. ²⁵²Department of Surgery, NYU Long Island School of Medicine, NYU Langone Hospital-Long Island, Mineola, New York, USA. ²⁵³Infection Prevention and Control, Infectious Disease Service, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. ²⁵⁴Department of Abdominal Surgery, University Medical Center Ljubljana, Ljubljana, Slovenia. ²⁵⁵Faculty of Medicine, Riga Stradins University, Riga, Latvia. ²⁵⁶Department of General and Emergency Surgery, Riga East Clinical University Hospital, Latvia. ²⁵⁷Department of Surgical Science, Emergency Surgery Unit, University of Cagliari, Cagliari, Italy. ²⁵⁸Infectious Diseases Department, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Vasco de Quiroga 15, Mexico City, Mexico. ²⁵⁹Department of Geriatric Medicine, Worcestershire Acute Hospitals NHS Foundation Trust, Worcestershire, UK. ²⁶⁰Universidad Autónoma de Santo Domingo, Instituto Nacional del Cáncer, Santo Domingo, Dominican Republic. ²⁶¹Laboratoire APEMAC, Centre Hospitalier Régional Universitaire de Nancy, and Centre regional en antibiothérapie du Grand Est, Université de Lorraine, Nancy, France. ²⁶²Department of General Surgery, Anadolu Medical Center Hospital, Kocaeli, Türkiye. ²⁶³Department of Digestive Surgery, CHU Amiens Picardie and University of Picardie Jules Verne, Amiens, France. ²⁶⁴Global Health eCore, Vall d'Hebron Institute of Research (VHIR), Ps. Vall d'Hebron 129, AMI-14, 08035, Barcelona, Spain. ²⁶⁵Unité de Recherche FOREVA, Réanimation Douleur Urgences, Centre Hospitalier Universitaire de Nîmes, Nîmes, France. ²⁶⁶Infectious Diseases Section, Hospital Regional de Taguatinga, Taguatinga, Brasília, Brazil. ²⁶⁷Department of Microbiology, The University of the West Indies, Mona, Jamaica. ²⁶⁸Infection Control, Hospital de Base, Brasília, Distrito Federal, Brazil. ²⁶⁹Department of Surgery, University of Minnesota, Minneapolis, Minnesota, USA. ²⁷⁰Infection and Antimicrobial Resistance Prevention and Control Unit, Centro Hospitalar Universitário São João, Porto, Portugal. ²⁷¹International Nosocomial Infection Control Consortium (INICC) Foundation, Miami, FL, USA. ²⁷²Department of Microbiology and Virology, University of Florence, Florence, Italy. ²⁷³Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy. ²⁷⁴Department of Internal Medicine, University of Botswana, Gaborone, Botswana. ²⁷⁵Wits School of Public Health, University of the Witwatersrand, Johannesburg, South Africa. ²⁷⁶Ministry of Health, Directorate-General for Health Prevention, Rome, Italy. ²⁷⁷Department of Infectious Diseases, Italian National Institute of Health, Rome, Italy. ²⁷⁸Clinic of Surgery, Lithuanian University of Health Sciences, Kaunas, Lithuania. ²⁷⁹Department of Community Medicine and Public Health, Suez Canal University, Ismailia, Egypt. ²⁸⁰Hôpital DOGTA-LAFIE, Lomé, Togo. ²⁸¹Pharmacology Department, School of Pharmacy, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia. ²⁸²Pharmacy Department, College of Medicine and Health Sciences, Arba Minch University, Arba Minch, Ethiopia. ²⁸³General Surgery Department, Military Teaching Hospital, Dakar, Senegal. ²⁸⁴Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ²⁸⁵Research Institute at Medical University Plovdiv/University Hospital St George, Plovdiv, Bulgaria. ²⁸⁶Department of Surgery, Western Michigan University School of Medicine, Kalamazoo, Michigan, USA. ²⁸⁷General Surgery Unit, Santa Maria Annunziata & Serristori Hospital, Firenze, Italy. ²⁸⁸Department

of Microbiology and Immunology, Weill Bugando School of Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania. ²⁸⁹Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA. ²⁹⁰Department of Internal Medicine, Texas A&M University, Houston, Texas, USA. ²⁹¹Emergency Surgery and Trauma-Fondazione Policlinico Universitario "A. Gemelli," Catholic University of Sacred Heart, Rome, Italy. ²⁹²Department of Surgery, Nordsjællands University Hospital, Hilleroed, Denmark. ²⁹³Lee Kong Chian School of Medicine, Nanyang Technological University, Novena, Singapore. ²⁹⁴Department of General Surgery, Tan Tock Seng Hospital, Novena, Singapore. ²⁹⁵Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wollo University, Dessie, Ethiopia. ²⁹⁶Department of Emergency Medicine, Ziekenhuis Geel, Geel, Belgium; Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Belgium. ²⁹⁷Faculty of Medicine, University of Leuven, Leuven, Belgium; Center for Research and Education in Emergency Care, University of Leuven, Leuven, Belgium. ²⁹⁸Institut Pasteur of Algeria, Algiers, Algeria. ²⁹⁹Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy. ³⁰⁰Division of Infectious Diseases, Department of Diagnostics and Public Health, University of Verona, Verona, Italy. ³⁰¹Intensive Care Unit, Saint Joseph-Saint Luc Hospital, Lyon, France. ³⁰²Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France. ³⁰³Hospital Central de Las Fuerzas Armadas, Santo Domingo, Dominican Republic. ³⁰⁴Infectious Diseases Department, AC Camargo Cancer Center, São Paulo, Brazil. ³⁰⁵Departemnt of Surgery, Saturnino Oral Provincial Hospital, Santiago de Cuba, Cuba. ³⁰⁶Division of Infectious Diseases and Geographic Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA. ³⁰⁷Department of Anesthesia, Bachmai University Hospital, Hanoi, Vietnam. ³⁰⁸Division of Ethics of Medicine, Medical Faculty, University of Augsburg, Augsburg, Germany. ³⁰⁹Medical and Infectious Diseases ICU, APHP Bichat Hospital F, Paris, France. ³¹⁰Infection, Antimicrobials, Modelling, Evolution, French Institute for Medical Research, University of Paris, Paris, France. ³¹¹Anesthesiology and Critical Care Units, Douala Laquintinie Hospital, Douala, Cameroon. ³¹²Institute of Microbiology, Biological and Environmental Sciences College, University San Francisco de Quito, Quito, Ecuador. ³¹³School of Medicine, European University Cyprus, Nicosia, Cyprus. ³¹⁴Unit of Antimicrobial Stewardship, Local Health Authority, City of Bologna, Bologna, Italy. ³¹⁵Laboratory of Emerging Infectious Diseases, School of Medicine, Pontificia Universidade Católica do Paraná, Curitiba, Paraná, Brazil. ³¹⁶First Department of Surgery, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, Prague, Czech Republic. ³¹⁷Section for Surgical Research, Department of Surgery, Medical University of Graz, Graz, Austria. ³¹⁸AMR Insights, Amsterdam, The Netherlands. ³¹⁹Department of Surgery, Radboud University Medical Center, Nijmegen, The Netherlands. ³²⁰Division of Trauma, Emergency Surgery, and Surgical Critical Care, Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA. ³²¹Department of Surgery, Medical School, University of Pecs, Pecs, Hungary. ³²²Department of Anesthesiology, Neuro-Intensive Care Unit, Careggi University Hospital, Florence, Italy. ³²³Department of Medical and Surgical Sciences, University of Bologna, S. Orsola-Malpighi Hospital, Bologna, Italy. ³²⁴Infectious Diseases Unit, Department for Integrated Infectious Risk Management, Istituto di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. ³²⁵Department of Clinical Microbiology, Center for Biomedical Diagnosis, Hospital Clinic-Universitat de Barcelona, Barcelona, Spain. ³²⁶Department of Basic Clinical Practice, School of Medicine, University of Barcelona, Barcelona, Spain. ³²⁷Barcelona Institute for Global Health, Barcelona, Spain. ³²⁸Department of Medical Microbiology and Infection Prevention, University Medical Center, Groningen, The Netherlands. ³²⁹Clinical Microbiology Department, Dr. Andrija Štampar Teaching Institute of Public Health, Zagreb, Croatia. ³³⁰Medical Microbiology Department, School of Medicine, University of Zagreb, Zagreb, Croatia. ³³¹Division of Infectious Diseases, Department of Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA. ³³²Coast General Teaching and Referral Hospital, Mombasa, Kenya. ³³³Antimicrobial Stewardship Committee, Prof. Dr. R.D. Kandou Central General Hospital, Manado, Indonesia. ³³⁴Division of Infectious Diseases, Hospital Rudolfstiftung, Wien, Austria. ³³⁵The National Chamber of Innovative Healthcare of the Republic of Uzbekistan, Tashkent, Uzbekistan. ³³⁶Department of Medical Microbiology and Parasitology, Faculty of Basic Clinical Sciences, College of Health Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria. ³³⁷General Surgery Department, Zliten Medical Center, Zliten, Libya. ³³⁸State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases,

Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. ³³⁹Department of Surgery, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, Kota Bharu, Malaysia. ³⁴⁰Section of Trauma and Acute Care Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA. ³⁴¹Universidad Peruana Cayetano Heredia, Facultad de Salud Pública y Administración, Lima, Peru. ³⁴²Institute of Global Health Innovation, St. Mary's Hospital, Imperial College London, London, UK. ³⁴³Antimicrobial Stewardship Project, Provincial Hospital of Bolzano, Bolzano, Italy. ³⁴⁴Department of Surgery, "Bufalini" Hospital, Cesena, Italy.

Author contributions

MS wrote the original draft. PSB provided English-language editing. All authors were contributors in reviewing and editing the manuscript. All authors read and approved the final manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Availability of data and materials

Not applicable.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 23 August 2023 Accepted: 23 September 2023

Published online: 16 October 2023

References

1. Anonymous. A global declaration on appropriate use of antimicrobial agents across the surgical pathway. *Surg Infect (Larchmt)*. 2017;18(8):846–53. <https://doi.org/10.1089/sur.2017.219>.
2. Charani E, McKee M, Ahmad R, Balasegaram M, Bonaconsa C, Merrett GB, et al. Optimising antimicrobial use in humans-review of current evidence and an interdisciplinary consensus on key priorities for research. *Lancet Reg Health Eur*. 2021;7:100161. <https://doi.org/10.1016/j.lanepe.2021.100161>.
3. International Pharmaceutical Federation (FIP). 2009 FIP global pharmacy workforce report. 2009. https://www.fip.org/files/fip/publications/2009_FIP_Global_Pharmacy_Workforce_Report.pdf. Accessed 12 July 2023.
4. Dhingra S, Rahman NAA, Peile E, Rahman M, Sartelli M, Hassali MA, et al. Microbial resistance movements: an overview of global public health threats posed by antimicrobial resistance, and how best to counter. *Front Public Health*. 2020;8:535668. <https://doi.org/10.3389/fpubh.2020.535668>.
5. Dutescu IA, Hillier SA. Encouraging the development of new antibiotics: Are financial incentives the right way forward? A systematic review and case study. *Infect Drug Resist*. 2021;14:415–34. <https://doi.org/10.2147/IDR.S287792>.
6. Renwick M, Mossialos E. What are the economic barriers of antibiotic R&D and how can we overcome them? *Expert Opin Drug Discov*. 2018;13(10):889–92. <https://doi.org/10.1080/17460441.2018.1515908>.
7. Renwick MJ, Brogan DM, Mossialos E. A systematic review and critical assessment of incentive strategies for discovery and development of novel antibiotics. *J Antibiot (Tokyo)*. 2016;69(2):73–88. <https://doi.org/10.1038/ja.2015.98>.

8. Jamrozik E, Selgelid M, editors. Ethics and drug resistance: collective responsibility for global public health. Heidelberg: Springer; 2020.
9. Plachouras D, Kärki T, Hansen S, Hopkins S, Lyytikäinen O, Moro ML, Point Prevalence Survey Study Group, et al. Antimicrobial use in European acute care hospitals: Results from the second point prevalence survey (PPS) of healthcare-associated infections and antimicrobial use, 2016 to 2017. *Euro Surveill*. 2018;23(46):1800393. <https://doi.org/10.2807/1560-7917.ES.23.46.1800393>.
10. Fridkin S, Baggs J, Fagan R, Magill S, Pollack LA, Malpiedi P, Centers for Disease Control and Prevention (CDC), et al. Vital signs: improving antibiotic use among hospitalized patients. *MMWR Morb Mortal Wkly Rep*. 2014;63(9):194–200.
11. Geller AI, Lovegrove MC, Shehab N, Hicks LA, Sapiiano MRP, Budnitz DS. National estimates of emergency department visits for antibiotic adverse events among adults—United States, 2011–2015. *J Gen Intern Med*. 2018;33(7):1060–8. <https://doi.org/10.1007/s11606-018-4430-x>.
12. Bauer KA, Kullar R, Gilchrist M, File TM Jr. Antibiotics and adverse events: the role of antimicrobial stewardship programs in “doing no harm.” *Curr Opin Infect Dis*. 2019;32(6):553–8. <https://doi.org/10.1097/QCO.0000000000000604>.
13. Tamma PD, Avdic E, Li DX, Dzintars K, Cosgrove SE. Association of adverse events with antibiotic use in hospitalized patients. *JAMA Intern Med*. 2017;177(9):1308–15. <https://doi.org/10.1001/jamainternmed.2018.6226>.
14. Silva ML, Cargnello C, Aulois-Griot M, Dumartin C. Antibiotic misuse: How to evaluate the costs? *Med Mal Infect*. 2019;49(7):485–94. <https://doi.org/10.1016/j.medmal.2019.03.012>.
15. Baur D, Gladstone BP, Burkert F, Carrara E, Foschi F, Döbele S, et al. Effect of antibiotic stewardship on the incidence of infection and colonisation with antibiotic-resistant bacteria and *Clostridium difficile* infection: a systematic review and meta-analysis. *Lancet Infect Dis*. 2017;17(9):990–1001. [https://doi.org/10.1016/S1473-3099\(17\)30325-0](https://doi.org/10.1016/S1473-3099(17)30325-0).
16. Global Alliance for Infections in Surgery. <https://www.infectionsinsurgery.org>. Accessed 12 July 2023.
17. Dahiya S, Chhillar AK, Sharma N, Choudhary P, Punia A, Balhara M, et al. *Candida auris* and nosocomial infection. *Curr Drug Targets*. 2020;21(4):365–73. <https://doi.org/10.2174/1389450120666190924155631>.
18. Dubey AK, Singla RK. Perspectives on anti-*Candida* drug development. *Curr Top Med Chem*. 2019;19:2375–6. <https://doi.org/10.2174/156802661928191206162925>.
19. Vassilopoulos S, Mylonakis E. Avenues for antifungal drug discovery and development: Where to now? *Expert Opin Drug Discov*. 2022;17:667–72. <https://doi.org/10.1080/17460441.2022.2098950>.
20. CDC. Antibiotic resistance threats in the United States, 2019. Atlanta: U.S. Department of Health and Human Services, CDC; 2019. www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 12 July 2023.
21. Lyman M, Forsberg K, Sexton DJ, Chow NA, Lockhart SR, Jackson BR, et al. Worsening spread of *Candida auris* in the United States, 2019 to 2021. *Ann Intern Med*. 2023;176(4):489–95. <https://doi.org/10.7326/M22-3469>.
22. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. *Candida auris* sp. Nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. *Microbiol Immunol*. 2009;53:41–4. <https://doi.org/10.1111/j.1348-0421.2008.00083.x>.
23. Kim MN, Shin JH, Sung H, Lee K, Kim EC, Ryoo N, et al. *Candida haemulonii* and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. *Clin Infect Dis*. 2009;48:e57–61. <https://doi.org/10.1086/597108>.
24. van Schalkwyk E, Mpenbe RS, Thomas J, Shuping L, Ismail H, Lowman W, GERMS-SA, et al. Epidemiologic shift in candidemia driven by *Candida auris*, South Africa, 2016–2017. *Emerg Infect Dis*. 2019;25:1698–707. <https://doi.org/10.3201/eid2509.190040>.
25. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, et al. Investigation of the first seven reported cases of *Candida auris*, a globally emerging invasive, multidrug-resistant fungus—United States, May 2013–August 2016. *Am J Transplant*. 2017;17:296–9. <https://doi.org/10.1111/ajt.14121>.
26. Borman AM, Szekealy A, Johnson EM. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen *Candida auris* and other key pathogenic *Candida* species. *mSphere*. 2016;1(4):e00189–e216. <https://doi.org/10.1128/mSphere.00189-16>.
27. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by *Candida auris*. *J Intensive Care*. 2018;6:69. <https://doi.org/10.1186/s40560-018-0342-4>.
28. Spivak ES, Hanson KE. *Candida auris*: an emerging fungal pathogen. *J Clin Microbiol*. 2018;56(2):e01588–e1617. <https://doi.org/10.1128/JCM.01588-17>.
29. Kean R, Brown J, Gulmez D, Ware A, Ramage G. *Candida auris*: a decade of understanding of an enigmatic pathogenic yeast. *J Fungi (Basel)*. 2020;6(1):30. <https://doi.org/10.3390/jof6010030>.
30. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH, Park KH, et al. First three reported cases of nosocomial fungemia caused by *Candida auris*. *J Clin Microbiol*. 2011;49(9):3139–42. <https://doi.org/10.1128/JCM.00319-11>.
31. Rossato L, Colombo AL. *Candida auris*: What have we learned about its mechanisms of pathogenicity? *Front Microbiol*. 2018;9:3081. <https://doi.org/10.3389/fmicb.2018.03081>.
32. Yue H, Bing J, Zheng Q, Zhang Y, Hu T, Du H, et al. Filamentation in *Candida auris*, an emerging fungal pathogen of humans: passage through the mammalian body induces a heritable phenotypic switch. *Emerg Microbes Infect*. 2018;7(1):188. <https://doi.org/10.1038/s41426-018-0187-x>.
33. Mayer FL, Wilson D, Hube B. *Candida albicans* pathogenicity mechanisms. *Virulence*. 2013;4(2):119–28. <https://doi.org/10.4161/viru.22913>.
34. Sartelli M, Weber DG, Ruppé E, Bassetti M, Wright BJ, Ansaloni L, et al. Antimicrobials: a global alliance for optimizing their rational use in intra-abdominal infections (AGORA). *World J Emerg Surg*. 2016;11:33. <https://doi.org/10.1186/s13017-016-0089-y>.
35. El-Halfawy OM, Valvano MA. Antimicrobial heteroresistance: an emerging field in need of clarity. *Clin Microbiol Rev*. 2015;28(1):191–207. <https://doi.org/10.1128/CMR.00058-14>.
36. Andersson DI, Nicoloff H, Hjort K. Mechanisms and clinical relevance of bacterial heteroresistance. *Nat Rev Microbiol*. 2019;17(8):479–96. <https://doi.org/10.1038/s41579-019-0218-1>.
37. Roca I, Akova M, Baquero F, Carlet J, Cavaleri M, Coenen S, et al. The global threat of antimicrobial resistance: science for intervention. *New Microbes New Infect*. 2015;6:22–9. <https://doi.org/10.1016/j.nmni.2015.02.007>.
38. Rice LB. Federal funding for the study of antimicrobial resistance in nosocomial pathogens: No ESKAPE. *J Infect Dis*. 2008;197(8):1079–81. <https://doi.org/10.1086/533452>.
39. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. *Clin Infect Dis*. 2009;48:1–12. <https://doi.org/10.1086/595011>.
40. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect*. 2012;18(3):268–81. <https://doi.org/10.1111/j.1469-0691.2011.03570.x>.
41. Kadri SS, Adjemian J, Lai YL, Spaulding AB, Ricotta E, Prevots DR, National Institutes of Health Antimicrobial Resistance Outcomes Research Initiative (NIH–ARORI), et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: Retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. *Clin Infect Dis*. 2018;67(12):1803–14. <https://doi.org/10.1093/cid/ciy378>.
42. Iskandar K, Molinier L, Hallit S, Sartelli M, Catena F, Coccolini F, et al. Drivers of antibiotic resistance transmission in low- and middle-income countries from a “one health” perspective—a review. *Antibiotics (Basel)*. 2020;9(7):372. <https://doi.org/10.3390/antibiotics9070372>.
43. Hollis A, Maybarduk P. Antibiotic resistance is a tragedy of the commons that necessitates global cooperation. *J Law Med Ethics*. 2015;43(Suppl 3):33–7.
44. One Health High-Level Expert Panel (OHHLEP), Adisasmito WB, Almuhairei S, Behraves CB, Biliogou P, Bukachi SA, et al. One Health: A new definition for a sustainable and healthy future. *PLoS Pathog*. 2022;18(6):e1010537. <https://doi.org/10.1371/journal.ppat.1010537>.

45. Venter H, Henningsen ML, Begg SL. Antimicrobial resistance in health-care, agriculture and the environment: the biochemistry behind the headlines. *Essays Biochem*. 2017;61(1):1–10. <https://doi.org/10.1042/EBC20160053>.
46. Crisci E. From open access to circular health: Ilaria Capua's journey through science and politics. *Viruses*. 2022;14(6):1296. <https://doi.org/10.3390/v14061296>.
47. Boudreau LeBlanc A, Williams-Jones B, Aenishaenslin C. Bioethics and one health: a case study approach to building reflexive governance. *Front Public Health*. 2022;18:311. <https://doi.org/10.3389/fpubh.2022.648593>.
48. Laxminarayan R, Duse A, Wattal C, Zaidi AK, Wertheim HF, Sumpradit N, et al. Antibiotic resistance—the need for global solutions. *Lancet Infect Dis*. 2013;13(12):1057–98. [https://doi.org/10.1016/S1473-3099\(13\)70318-9](https://doi.org/10.1016/S1473-3099(13)70318-9).
49. WHO. World Health Organization global action plan on antimicrobial resistance. 2015. <https://www.who.int/publications/i/item/9789241509763>. Accessed 12 July 2023.
50. Charani E, Mendelson M, Pallett SJC, Ahmad R, Mpundu M, Mbamalu O, et al. An analysis of existing national action plans for antimicrobial resistance—gaps and opportunities in strategies optimising antibiotic use in human populations. *Lancet Glob Health*. 2023;11(3):e466–74. [https://doi.org/10.1016/S2214-109X\(23\)00019-0](https://doi.org/10.1016/S2214-109X(23)00019-0).
51. Patel J, Harant A, Fernandes G, Mwamelo AJ, Hein W, Dekker D, et al. Measuring the global response to antimicrobial resistance, 2020–21: a systematic governance analysis of 114 countries. *Lancet Infect Dis*. 2023;3(6):706–18. [https://doi.org/10.1016/S1473-3099\(22\)00796-4](https://doi.org/10.1016/S1473-3099(22)00796-4).
52. Patel J, Sridhar D. The pandemic legacy of antimicrobial resistance in the USA. *Lancet Microbe*. 2022;3(10):e726–7. [https://doi.org/10.1016/S2666-5247\(22\)00227-0](https://doi.org/10.1016/S2666-5247(22)00227-0).
53. Nandi A, Pecetta S, Bloom DE. Global antibiotic use during the COVID-19 pandemic: analysis of pharmaceutical sales data from 71 countries, 2020–2022. *EclinicalMedicine*. 2023;5(7):101848. <https://doi.org/10.1016/j.eclinm.2023.101848>.
54. Langford BJ, So M, Simeonova M, Leung V, Lo J, Kan T, et al. Antimicrobial resistance in patients with COVID-19: a systematic review and meta-analysis. *Lancet Microbe*. 2023;4(3):e179–91. [https://doi.org/10.1016/S2666-5247\(22\)00355-X](https://doi.org/10.1016/S2666-5247(22)00355-X).
55. Brink AJ, Richards G, Tootla H, Prentice E. Epidemiology of Gram-negative bacteria during coronavirus disease 2019. What is the real pandemic? *Curr Opin Infect Dis*. 2022;35(6):595–604. <https://doi.org/10.1097/QCO.0000000000000864>.
56. Langford BJ, Soucy JR, Leung V, So M, Kwan ATH, Portnoff JS, et al. Antibiotic resistance associated with the COVID-19 pandemic: a systematic review and meta-analysis. *Clin Microbiol Infect*. 2022. <https://doi.org/10.1016/j.cmi.2022.12.006>.
57. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet*. 2022;399(10325):629–55. [https://doi.org/10.1016/S0140-6736\(21\)02724-0](https://doi.org/10.1016/S0140-6736(21)02724-0).
58. Laxminarayan R. The overlooked pandemic of antimicrobial resistance. *Lancet*. 2022;399(10325):606–7. [https://doi.org/10.1016/S0140-6736\(22\)00087-3](https://doi.org/10.1016/S0140-6736(22)00087-3).
59. Makoka MH, Miller WC, Hoffman IF, Cholera R, Gilligan PH, Kamwendo D, et al. Bacterial infections in Lilongwe, Malawi: Aetiology and antibiotic resistance. *BMC Infect Dis*. 2012;12:67. <https://doi.org/10.1186/1471-2334-12-67>.
60. Ouedraogo AS, Jean Pierre H, Bañuls AL, Ouédraogo R, Godreuil S. Emergence and spread of antibiotic resistance in West Africa: contributing factors and threat assessment. *Med Sante Trop*. 2017;27(2):147–54. <https://doi.org/10.1684/mst.2017.0678>.
61. Lancet T. Redefining vulnerability in the era of COVID-19. *Lancet*. 2020;395(10230):1089. [https://doi.org/10.1016/S0140-6736\(20\)30757-1](https://doi.org/10.1016/S0140-6736(20)30757-1).
62. Alividza V, Mariano V, Ahmad R, Charani E, Rawson TM, Holmes AH, et al. Investigating the impact of poverty on colonization and infection with drug-resistant organisms in humans: a systematic review. *Infect Dis Poverty*. 2018;7(1):76. <https://doi.org/10.1186/s40249-018-0459-7>.
63. Holmes AH, Sharland M. The Chennai Declaration: India's landmark national commitment to antibiotic stewardship demonstrates that "truth alone triumphs." *J Antimicrob Chemother*. 2013;68(7):1453–4.
64. O'Neill J. Tackling drug-resistant infections globally: final report and recommendations. The review on antimicrobial resistance. 2016. https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf. Accessed 12 July 2023.
65. Jonas O, Irwin A, Berthe FCJ, Le Gall FG, Marquez PV. Drug-resistant infections: a threat to our economic future (vol 2): final report (English). HNP/Agriculture Global Antimicrobial Resistance Initiative Washington, D.C.: World Bank Group. <http://documents.worldbank.org/curated/en/323311493396993758/final-report>. Accessed 12 July 2023.
66. de Kraker ME, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? *PLoS Med*. 2016;13(11):e1002184. <https://doi.org/10.1371/journal.pmed.1002184>.
67. Global Health Hub Germany. Results of the G7 health ministers' meeting in Berlin, 19–20 May 2022. <https://www.globalhealthhub.de/de/news/detail/g7-health-ministers-unite-to-secure-a-healthy-future-results-of-the-g7-health-ministers-meeting-in-berlin-may-19-20-2022>. Accessed 12 July 2023.
68. Anderson M, Schulze K, Cassini A, Plachouras D, Mossialos E. A governance framework for development and assessment of national action plans on antimicrobial resistance. *Lancet Infect Dis*. 2019;19(11):e371–84. [https://doi.org/10.1016/S1473-3099\(19\)30415-3](https://doi.org/10.1016/S1473-3099(19)30415-3).
69. Kiggundu R, Lusaya E, Seni J, Waswa JP, Kakooza F, Tjipura D, et al. Identifying and addressing challenges to antimicrobial use surveillance in the human health sector in low- and middle-income countries: experiences and lessons learned from Tanzania and Uganda. *Antimicrob Resist Infect Control*. 2023;12(1):9. <https://doi.org/10.1186/s13756-023-01213-3>.
70. Ren M, So AD, Chandy SJ, Mpundu M, Peralta AQ, Åkerfeldt K, et al. Equitable access to antibiotics: a core element and shared global responsibility for pandemic preparedness and response. *J Law Med Ethics*. 2022;50(S2):34–9. <https://doi.org/10.1017/jme.2022.77>.
71. Broom A, Kenny K, Prainsack B, Broom J. Antimicrobial resistance as a problem of values? Views from three continents. *Crit Public Health*. 2021;31(4):451–63. <https://doi.org/10.1080/09581596.2020.1725444>.
72. Council of the EU and the European Council. Tackling antimicrobial resistance: council adopts recommendation. <https://www.consilium.europa.eu/en/press/press-releases/2023/06/13/tackling-antimicrobial-resistance-council-adopts-recommendation/>. Accessed 12 July 2023.
73. Ndaki PM, Mushi MF, Mwanga JR, Konje ET, Ntinginya NE, Mmbaga BT, et al. Dispensing antibiotics without prescription at community pharmacies and accredited drug dispensing outlets in Tanzania: a cross-sectional study. *Antibiotics (Basel)*. 2021;10(8):1025. <https://doi.org/10.3390/antibiotics10081025>.
74. Kaprou GD, Bergšpica I, Alexa EA, Alvarez-Ordóñez A, Prieto M. Rapid methods for antimicrobial resistance diagnostics. *Antibiotics (Basel)*. 2021;10(2):209. <https://doi.org/10.3390/antibiotics10020209>.
75. Charani E, Ahmad R, Rawson TM, Castro-Sánchez E, Tarrant C, Holmes AH. The differences in antibiotic decision-making between acute surgical and acute medical teams: an ethnographic study of culture and team dynamics. *Clin Infect Dis*. 2019;69(1):12–20. <https://doi.org/10.1093/cid/ciy844>.
76. Cantón R, Horcajada JP, Oliver A, Garbajosa PR, Vila J. Inappropriate use of antibiotics in hospitals: the complex relationship between antibiotic use and antimicrobial resistance. *Enferm Infect Microbiol Clin*. 2013;31(Suppl 4):3–11. [https://doi.org/10.1016/S0213-005X\(13\)70126-5](https://doi.org/10.1016/S0213-005X(13)70126-5).
77. Levy Hara G, Rojas-Cortés R, Molina León HF, Dreser Mansilla A, Alfonso Orta I, Rizo-Amezquita JN, et al. Point prevalence survey of antibiotic use in hospitals in Latin American countries. *J Antimicrob Chemother*. 2022;77(3):807–15. <https://doi.org/10.1093/jac/dkac459>.
78. Sartelli M, Duane TM, Catena F, Tessier JM, Coccolini F, Kao LS, et al. Antimicrobial stewardship: a call to action for surgeons. *Surg Infect (Larchmt)*. 2016;17(6):625–31. <https://doi.org/10.1089/sur.2016.187>.
79. Goff DA, Kullar R, Goldstein EJC, Gilchrist M, Nathwani D, Cheng AC, et al. A global call from five countries to collaborate in antibiotic stewardship: United we succeed, divided we might fail. *Lancet Infect Dis*. 2017;17(2):e56–63. [https://doi.org/10.1016/S1473-3099\(16\)30386-3](https://doi.org/10.1016/S1473-3099(16)30386-3).
80. Doron S, Davidson LE. Antimicrobial stewardship. *Mayo Clin Proc*. 2011;86(11):1113–23. <https://doi.org/10.4065/mcp.2011.0358>.
81. Dyar OJ, Huttner B, Schouten R, Pulcini C, ESGAP (ESCMID Study Group for Antimicrobial stewardship). What is antimicrobial stewardship? *Clin*

- Microbiol Infect. 2017;23(11):793–8. <https://doi.org/10.1016/j.cmi.2017.08.026>.
82. Kpokiri EE, Ladva M, Dodoo CC, Orman E, Aku TA, Mensah A, et al. Knowledge, awareness and practice with antimicrobial stewardship programmes among healthcare providers in a Ghanaian tertiary hospital. *Antibiotics* (Basel). 2021;11(1):6. <https://doi.org/10.3390/antibiotic11010006>.
 83. Retamar P, Rodríguez-Baño J. A step forward in the definition of antimicrobial stewardship indicators: better measurements, better work. *Farm Hosp*. 2019;43(3):77–8. <https://doi.org/10.7399/fh.11238>.
 84. Dryden M, Johnson AP, Ashiru-Oredope D, Sharland M. Using antibiotics responsibly: right drug, right time, right dose, right duration. *J Antimicrob Chemother*. 2011;66(11):2441–3. <https://doi.org/10.1093/jac/ckr370>.
 85. Kakkar AK, Shafiq N, Singh G, Ray P, Gautam V, Agarwal R, et al. Antimicrobial stewardship programs in resource constrained environments: understanding and addressing the need of the systems. *Front Public Health*. 2020;8:140. <https://doi.org/10.3389/fpubh.2020.00140>.
 86. Godman B, Egwuenu A, Haque M, Malande OO, Schellack N, Kumar S, et al. Strategies to improve antimicrobial utilization with a special focus on developing countries. *Life* (Basel). 2021;11(6):528. <https://doi.org/10.3390/life11060528>.
 87. Dyar OJ, Moran-Gilad J, Greub G, Pulcini C, ESGMD Executive Committee and the ESGAP Executive Committee. Diagnostic stewardship: Are we using the right term? *Clin Microbiol Infect*. 2019;25(3):272–3. <https://doi.org/10.1016/j.cmi.2018.12.011>.
 88. Patel R, Fang FC. Diagnostic stewardship: opportunity for a laboratory-infectious diseases partnership. *Clin Infect Dis*. 2018;67(5):799–801. <https://doi.org/10.1093/cid/ciy077>.
 89. Dellit TH, Owens RC, McGowan JE Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. *Clin Infect Dis*. 2007;44(2):159–77. <https://doi.org/10.1086/510393>.
 90. Veceli T, Rello J. Optimization of antimicrobial prescription in the hospital. *Eur J Intern Med*. 2022;106:39–44. <https://doi.org/10.1016/j.ejim.2022.08.035>.
 91. Safdar N, Abad C. Educational interventions for prevention of healthcare-associated infection: a systematic review. *Crit Care Med*. 2008;36(3):933–40. <https://doi.org/10.1097/CCM.0B013E318165FAF3>.
 92. Ward DJ. The role of education in the prevention and control of infection: a review of the literature. *Nurse Educ Today*. 2011;31(1):9–17. <https://doi.org/10.1016/j.nedt.2010.03.007>.
 93. Carlet J, Astagneau P, Brun-Buisson C, Coignard B, Salomon V, Tran B, French National Program for Prevention of Healthcare-Associated Infections and Antimicrobial Resistance, et al. French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992–2008: positive trends, but perseverance needed. *Infect Control Hosp Epidemiol*. 2009;30(8):737–45. <https://doi.org/10.1086/598682>.
 94. Alhumaid S, Al Mutair A, Al Alawi Z, Alsuliman M, Ahmed GY, Rabaan AA, et al. Knowledge of infection prevention and control among healthcare workers and factors influencing compliance: a systematic review. *Antimicrob Resist Infect Control*. 2021;10(1):86. <https://doi.org/10.1186/s13756-021-00957-0>.
 95. Sartelli M, Pagani L, Iannazzo S, Moro ML, Viale P, Pan A, et al. A proposal for a comprehensive approach to infections across the surgical pathway. *World J Emerg Surg*. 2020;15(1):13. <https://doi.org/10.1186/s13017-020-00295-3>.
 96. Sartelli M, Labricciosa FM, Coccolini F, Coimbra R, Abu-Zidan FM, Ansaloni L, et al. It is time to define an organizational model for the prevention and management of infections along the surgical pathway: a worldwide cross-sectional survey. *World J Emerg Surg*. 2022;17(1):17. <https://doi.org/10.1186/s13017-020-00295-3>.
 97. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, Burden of AMR Collaborative Group, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: A population-level modelling analysis. *Lancet Infect Dis*. 2019;19(1):56–66. [https://doi.org/10.1016/S1473-3099\(18\)30605-4](https://doi.org/10.1016/S1473-3099(18)30605-4).
 98. Suetens C, Latour K, Kärki T, Ricchizzi E, Kinross P, Moro ML, et al. Prevalence of healthcare-associated infections, estimated incidence and composite antimicrobial resistance index in acute care hospitals and long-term care facilities: results from two European point prevalence surveys, 2016 to 2017. *Euro Surveill*. 2018;23(46):1800516. <https://doi.org/10.2807/1560-7917.ES.2018.23.46.1800516>.
 99. Cassini A, Plachouras D, Eckmanns T, Abu Sin M, Blank HP, Ducomble T, et al. Burden of six healthcare-associated infections on European population health: estimating incidence-based disability-adjusted life years through a population prevalence-based modelling study. *PLoS Med*. 2016;13(10):e1002150. <https://doi.org/10.1371/journal.pmed.1002150>.
 100. Schreiber PW, Sax H, Wolfensberger A, Clack L, Kuster SP, Swissnos. The preventable proportion of healthcare-associated infections 2005–2016: systematic review and meta-analysis. *Infect Control Hosp Epidemiol*. 2018;39:1277–95. <https://doi.org/10.1017/ice.2018.183>.
 101. World Health Organization. WHO guidelines on hand hygiene in health care. Geneva: World Health Organization; 2009. <https://www.who.int/publications/i/item/9789241597906>. Accessed 12 July 2023.
 102. Boyce JM, Pittet D, Healthcare Infection Control Practices Advisory Committee, HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Society for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Diseases Society of America. *MMWR Recomm Rep*. 2002;51(16):1–45.
 103. Glowicz JB, Landon E, Sickbert-Bennett EE, Aiello AE, deKay K, Hoffmann KK, et al. SHEA/IDSA/APIC practice recommendation: strategies to prevent healthcare-associated infections through hand hygiene: 2022 Update. *Infect Control Hosp Epidemiol*. 2023;44(3):355–76. <https://doi.org/10.1017/ice.2022.304>.
 104. Sax H, Allegranzi B, Uçkay I, Larson E, Boyce J, Pittet D. “My five moments for hand hygiene”: a user-centred design approach to understand, train, monitor and report hand hygiene. *J Hosp Infect*. 2007;67(1):9–21. <https://doi.org/10.1016/j.jhin.2015.04.011>.
 105. Erasmus V, Dahan TJ, Brug H, Richardus JH, Behrendt MD, Vos MC, et al. Systematic review of studies on compliance with hand hygiene guidelines in hospital care. *Infect Control Hosp Epidemiol*. 2010;31(3):283–94. <https://doi.org/10.1086/650451>.
 106. Kirk J, Kendall A, Marx JF, Pincock T, Young E, Hughes JM, Landers T. Point of care hand hygiene—where’s the rub? A survey of US and Canadian health care workers’ knowledge, attitudes, and practices. *Am J Infect Control*. 2016;44(10):1095–101. <https://doi.org/10.1016/j.ajic.2016.03.005>.
 107. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis*. 2016;16:e288–303. [https://doi.org/10.1016/S1473-3099\(16\)30402-9](https://doi.org/10.1016/S1473-3099(16)30402-9).
 108. Allegranzi B, Bischoff P, de Jonge S, Kubilay NZ, Zayed B, Gomes SM, et al. New WHO recommendations on preoperative measures for surgical site infection prevention: an evidence-based global perspective. *Lancet Infect Dis*. 2016;16:e276–287. [https://doi.org/10.1016/S1473-3099\(16\)30398-X](https://doi.org/10.1016/S1473-3099(16)30398-X).
 109. Berrios-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, et al. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. *JAMA Surg*. 2017;152:784–91. <https://doi.org/10.1001/jamasurg.2017.0904>.
 110. World Health Organization. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level. Geneva: World Health Organization; 2016. <https://apps.who.int/iris/handle/10665/251730>. Accessed 12 July 2023.
 111. Storr J, Twyman A, Zingg W, Damani N, Kilpatrick C, Reilly J, et al. Core components for effective infection prevention and control programmes: new WHO evidence-based recommendations. *Antimicrob Resist Infect Control*. 2017;6:6. <https://doi.org/10.1186/s13756-016-0149-9>.
 112. Sydnor ER, Perl TM. Hospital epidemiology and infection control in acute-care settings. *Clin Microbiol Rev*. 2011;24(1):141–73. <https://doi.org/10.1128/CMR.00027-10>.
 113. Zingg W, Holmes A, Dettenkofer M, Goetting T, Secci F, Clack L, et al. Hospital organisation, management, and structure for prevention of

- health-care-associated infection: a systematic review and expert consensus. *Lancet Infect Dis*. 2015;15(2):212–24. [https://doi.org/10.1016/S1473-3099\(14\)70854-0](https://doi.org/10.1016/S1473-3099(14)70854-0).
114. Tomczyk S, Twyman A, de Kraker MEA, Coutinho Rehse AP, Tartari E, Toledo JP, et al. The first WHO global survey on infection prevention and control in health-care facilities. *Lancet Infect Dis*. 2022;22(6):845–56. [https://doi.org/10.1016/S1473-3099\(21\)00809-4](https://doi.org/10.1016/S1473-3099(21)00809-4).
 115. Brink AJ, Richards GA. Antimicrobial stewardship: leveraging the “butterfly effect” of hand hygiene. *Antibiotics (Basel)*. 2022;11(10):1348. <https://doi.org/10.3390/antibiotics11101348>.
 116. Mills JP, Marchaim D. Multidrug-resistant gram-negative bacteria: infection prevention and control update. *Infect Dis Clin N Am*. 2021;35(4):969–94. <https://doi.org/10.1016/j.idc.2021.08.001>.
 117. Guidelines for the prevention and control of carbapenem-resistant Enterobacteriaceae, *Acinetobacter baumannii* and *Pseudomonas aeruginosa* in health care facilities. Geneva: World Health Organization; 2017. <https://www.ncbi.nlm.nih.gov/books/NBK493061/>. Accessed 12 July 2023.
 118. Tomczyk S, Zanichelli V, Grayson ML, Twyman A, Abbas M, Pires D, et al. Control of carbapenem-resistant Enterobacteriaceae, *Acinetobacter baumannii*, and *Pseudomonas aeruginosa* in healthcare facilities: a systematic review and reanalysis of quasi-experimental studies. *Clin Infect Dis*. 2019;68(5):873–84. <https://doi.org/10.1093/cid/ciy752>.
 119. Micoli F, Bagnoli F, Rappuoli R, Serruto D. The role of vaccines in combating antimicrobial resistance. *Nat Rev Microbiol*. 2021;19(5):287–302. <https://doi.org/10.1038/s41579-020-00506-3>.
 120. Merakou C, Schaefer MM, Priebe GP. Progress toward the elusive *Pseudomonas aeruginosa* vaccine. *Surg Infect (Larchmt)*. 2018;19(8):757–68. <https://doi.org/10.1089/sur.2018.233>.
 121. Barie PS, Narayan M, Sawyer RG. Immunization against *Staphylococcus aureus* infections. *Surg Infect (Larchmt)*. 2018;19(8):750–6. <https://doi.org/10.1089/sur.2018.263>.
 122. Sihvonen R, Siira L, Toropainen M, Kuusela P, Patari-Sampo A. *Streptococcus pneumoniae* antimicrobial resistance decreased in the Helsinki metropolitan area after routine 10-valent pneumococcal conjugate vaccination of infants in Finland. *Eur J Clin Microbiol Infect Dis*. 2017;36:2109–16. <https://doi.org/10.1007/s10096-017-3033-5>.
 123. Jansen KU, Anderson AS. The role of vaccines in fighting antimicrobial resistance (AMR). *Hum Vaccin Immunother*. 2018;14(9):2142–9. <https://doi.org/10.1080/21645515.2018.1476814>.
 124. Tekle YI, Nielsen KM, Liu J, Pettigrew MM, Meyers LA, Galvani AP, et al. Controlling antimicrobial resistance through targeted, vaccine-induced replacement of strains. *PLoS ONE*. 2012;7:e50688. <https://doi.org/10.1371/journal.pone.0050688>.
 125. Mina MJ, Kula T, Leng Y, Li M, de Vries RD, Knip M, et al. Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. *Science*. 2019;366(6465):599–606. <https://doi.org/10.1126/science.aay6485>.
 126. Dionne B, Dehority W, Brett M, Howdieshell TR. The asplenic patient: post-insult immunocompetence, infection, and vaccination. *Surg Infect (Larchmt)*. 2017;18(5):536–44. <https://doi.org/10.1089/sur.2016.267>.
 127. Gabutti G. Available evidence and potential for vaccines for reduction in antibiotic prescriptions. *Hum Vaccin Immunother*. 2022;18(7):2151291. <https://doi.org/10.1080/21645515.2022.2151291>.
 128. Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. *Immunol Rev*. 2017;279(1):90–105. <https://doi.org/10.1111/imr.12563>.
 129. Donskey CJ. Antibiotic regimens and intestinal colonization with antibiotic-resistant gram-negative bacilli. *Clin Infect Dis*. 2006;43(Suppl 2):S62–9. <https://doi.org/10.1086/504481>.
 130. Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. *Trends Microbiol*. 2004;12:412–6. <https://doi.org/10.1016/j.tim.2004.07.004>.
 131. Bhalla A, Pultz NJ, Ray AJ, Hoyer CK, Eckstein EC, Donskey CJ. Antianaerobic antibiotic therapy promotes overgrowth of antibiotic-resistant, gram-negative bacilli and vancomycin-resistant enterococci in the stool of colonized patients. *Infect Control Hosp Epidemiol*. 2003;24(9):644–9. <https://doi.org/10.1086/502267>.
 132. Donskey CJ, Chowdhry TK, Hecker MT, Hoyer CK, Hanrahan JA, Hujer AM, et al. Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients. *N Engl J Med*. 2000;343(26):1925–32. <https://doi.org/10.1056/NEJM200012283432604>.
 133. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. *Clin Infect Dis*. 2012;55(7):905–14. <https://doi.org/10.1093/cid/cis580>.
 134. Ruppé E, Lixandru B, Cocjocar R, Büke C, Paramythiotou E, Angebault C, et al. Relative fecal abundance of extended-spectrum- β -lactamase-producing *Escherichia coli* strains and their occurrence in urinary tract infections in women. *Antimicrob Agents Chemother*. 2013;57(9):4512–7. <https://doi.org/10.1128/AAC.00238-13>.
 135. Rashid MU, Zaura E, Buijs MJ, Keijser BJ, Crielaard W, Nord CE, et al. Determining the long-term effect of antibiotic administration on the human normal intestinal microbiota using culture and pyrosequencing methods. *Clin Infect Dis*. 2015;60(Suppl 2):S77–84. <https://doi.org/10.1093/cid/civ137>.
 136. Lindgren M, Lofmark S, Edlund C, Huovinen P, Jalava J. Prolonged impact of a one-week course of clindamycin on *Enterococcus* spp. in human normal microbiota. *Scand J Infect Dis*. 2009;41(3):215–9. <https://doi.org/10.1080/00365540802651897>.
 137. Patangia DV, Anthony Ryan C, Dempsey E, Paul Ross R, Stanton C. Impact of antibiotics on the human microbiome and consequences for host health. *Microbiol Open*. 2022;11(1):e1260. <https://doi.org/10.1002/mbio.1260>.
 138. De La Cochetière MF, Durand T, Lepage P, Bourrelle A, Galmiche JP, Doré J. Resilience of the dominant human fecal microbiota upon short-course antibiotic challenge. *J Clin Microbiol*. 2005;43(11):5588–92. <https://doi.org/10.1128/JCM.43.11.5588-5592.2005>.
 139. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS Biol*. 2008;6(11):e280. <https://doi.org/10.1371/journal.pbio.0060280>.
 140. Raymond F, Ouameur AA, Déraspe M, Iqbal N, Gingras H, Dridi B, et al. The initial state of the human gut microbiome determines its reshaping by antibiotics. *ISME J*. 2016;10(3):707–20. <https://doi.org/10.1038/ismej.2015.148>.
 141. Zhang L, Huang Y, Zhou Y, Buckley T, Wang HH. Antibiotic administration routes significantly influence the levels of antibiotic resistance in gut microbiota. *Antimicrob Agents Chemother*. 2013;57(8):3659–66. <https://doi.org/10.1128/AAC.00670-13>.
 142. Solbach P, Chhatwal P, Woltemate S, Tacconelli E, Buhl M, Autenrieth IB, et al. Microbiota-associated risk factors for *Clostridioides difficile* acquisition in hospitalized patients: a prospective, multicentric study. *Clin Infect Dis*. 2021;73(9):e2625–34. <https://doi.org/10.1093/cid/ciaa871>.
 143. Aguilar RC, Salmanton-García J, Carney J, Böll B, Kochanek M, Jazmati N, et al. *Clostridioides difficile* infections in the intensive care unit: a monocentric cohort study. *Infection*. 2020;48(3):421–7. <https://doi.org/10.1007/s15010-020-01413-8>.
 144. Sartelli M, Di Bella S, McFarland LV, Khanna S, Furuya-Kanamori L, Abuzeid N, et al. 2019 update of the WSES guidelines for management of *Clostridioides (Clostridium) difficile* infection in surgical patients. *World J Emerg Surg*. 2019;14:8. <https://doi.org/10.1186/s13017-015-0033-6>.
 145. Farrell RJ, LaMont JT. Pathogenesis and clinical manifestations of *Clostridium difficile* diarrhea and colitis. *Curr Top Microbiol Immunol*. 2000;250:109–25. https://doi.org/10.1007/978-3-662-06272-2_6.
 146. Britton RA, Young VB. Role of the intestinal microbiota in resistance to colonization by *Clostridium difficile*. *Gastroenterology*. 2014;146(6):1547–53. <https://doi.org/10.1053/j.gastro.2014.01.059>.
 147. Kachrimanidou M, Tsintarakis E. Insights into the role of human gut microbiota in *Clostridioides difficile* infection. *Microorganisms*. 2020;8(2):200. <https://doi.org/10.3390/microorganisms8020200>.
 148. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. *Surg Infect (Larchmt)*. 2013;14(1):73–156. <https://doi.org/10.1089/sur.2013.9999>.
 149. Sartelli M, Boermeester MA, Cainzos M, Coccolini F, de Jonge SW, Rasa K, et al. Six long-standing questions about antibiotic prophylaxis in surgery. *Antibiotics (Basel)*. 2023;12(5):908. <https://doi.org/10.3390/antibiotics12050908>.

150. Yin Y, Song T, Liao B, Luo Q, Zhou Z. Antibiotic prophylaxis in patients undergoing open mesh repair of inguinal hernia: a meta-analysis. *Am Surg*. 2012;78:359–65. <https://doi.org/10.1177/000313481207800348>.
151. Al Riyees L, Al Madani W, Firwana N, Balkhy HH, Ferwana M, Alkhudhayri A. Antibiotic prophylaxis against surgical site infection after open hernia surgery: a systematic review and meta-analysis. *Eur Surg Res*. 2021;62:121–33. <https://doi.org/10.1159/000517404>.
152. Erdas E, Medas F, Pisano G, Nicolosi A, Calò PG. Antibiotic prophylaxis for open mesh repair of groin hernia: systematic review and meta-analysis. *Hernia*. 2016;20:765–76. <https://doi.org/10.1007/s10029-016-1536-0>.
153. Orelia CC, van Hessen C, Sanchez-Manuel FJ, Aufenacker TJ, Scholten RJ. Antibiotic prophylaxis for prevention of postoperative wound infection in adults undergoing open elective inguinal or femoral hernia repair. *Cochrane Database Syst Rev*. 2020;4:CD003769. <https://doi.org/10.1002/14651858.CD003769.pub5>.
154. Mazaki T, Mado K, Masuda H, Shiono M. Antibiotic prophylaxis for the prevention of surgical site infection after tension-free hernia repair: a Bayesian and frequentist meta-analysis. *J Am Coll Surg*. 2013;217(788–801):e1–4. <https://doi.org/10.1016/j.jamcollsurg.2013.07.386>.
155. Boonchan T, Wilasrusmee C, McEvoy M, Attia J, Thakkinstian A. Network meta-analysis of antibiotic prophylaxis for prevention of surgical-site infection after groin hernia surgery. *Br J Surg*. 2017;104(2):e106–17. <https://doi.org/10.1002/bjs.10441>.
156. HerniaSurge Group. International guidelines for groin hernia management. *Hernia*. 2018;22:1–165. <https://doi.org/10.1007/s10029-017-1668-x>.
157. Reiffel AJ, Barie PS, Spector JA. A multi-disciplinary review of the potential association between closed-suction drains and surgical site infection. *Surg Infect (Larchmt)*. 2013;14(3):244–69. <https://doi.org/10.1089/sur.2011.126>.
158. Leekha S, Terrell CL, Edson RS. General principles of antimicrobial therapy. *Mayo Clin Proc*. 2011;86(2):156–67. <https://doi.org/10.4065/mcp.2010.0639>.
159. Cai T, Nesi G, Mazzoli S, Meacci F, Lanzafame P, Caciagli P, et al. Asymptomatic bacteriuria treatment is associated with a higher prevalence of antibiotic resistant strains in women with urinary tract infections. *Clin Infect Dis*. 2015;61(11):1655–61. <https://doi.org/10.1093/cid/civ696>.
160. Cash MC, Hile G, Johnson J, Stone T, Smith J, Ohl C, et al. Sustained impact of an antibiotic stewardship initiative targeting asymptomatic bacteriuria and pyuria in the emergency department. *Antimicrob Steward Healthc Epidemiol*. 2022;2(1):e148. <https://doi.org/10.1017/ash.2022.289>.
161. Chabok A, Pählman L, Hjern F, Haapaniemi S, Smedh K, AVOD Study Group. Randomized clinical trial of antibiotics in acute uncomplicated diverticulitis. *Br J Surg*. 2012;99(4):532–9. <https://doi.org/10.1002/bjs.8688>.
162. Daniels L, Ünlü Ç, de Korte N, van Dieren S, Stockmann HB, Vrouwenraets BC, et al. Randomized clinical trial of observational versus antibiotic treatment for a first episode of CT-proven uncomplicated acute diverticulitis. *Br J Surg*. 2017;104(1):52–61. <https://doi.org/10.1002/bjs.10309>.
163. Jaung R, Nisbet S, Gosselink MP, Di Re A, Keane C, Lin A, et al. Antibiotics do not reduce length of hospital stay for uncomplicated diverticulitis in a pragmatic double-blind randomized trial. *Clin Gastroenterol Hepatol*. 2021;19(3):503–510.e1. <https://doi.org/10.1016/j.cgh.2020.03.049>.
164. Mali JP, Mentula PJ, Leppäniemi AK, Sallinen VJ. Symptomatic treatment for uncomplicated acute diverticulitis: a prospective cohort study. *Dis Colon Rectum*. 2016;59(6):529–34. <https://doi.org/10.1097/DCR.0000000000000579>.
165. Estrada Ferrer O, Ruiz Edo N, Hidalgo Grau LA, Abadal Prades M, Del Bas Rubia M, Garcia Torralbo EM, et al. Selective non-antibiotic treatment in sigmoid diverticulitis: Is it time to change the traditional approach? *Tech Coloproctol*. 2016;20(5):309–15. <https://doi.org/10.1007/s10151-016-1464-0>.
166. Barie PS, Kao LS, Moody M, Sawyer RG. Infection or inflammation: Are uncomplicated acute appendicitis, acute cholecystitis, and acute diverticulitis infectious diseases? *Surg Infect (Larchmt)*. 2023;24(2):99–111. <https://doi.org/10.1089/sur.2022.363>.
167. Chabok A, Thorisson A, Nikberg M, Schultz JK, Sallinen V. Changing paradigms in the management of acute uncomplicated diverticulitis. *Scand J Surg*. 2021;110(2):180–6. <https://doi.org/10.1177/14574969211011032>.
168. de Jonge SW, Gans SL, Atema JJ, Solomkin JS, Dellinger PE, Boermeester MA. Timing of preoperative antibiotic prophylaxis in 54,552 patients and the risk of surgical site infection: a systematic review and meta-analysis. *Medicine*. 2017;96:e6903. <https://doi.org/10.1097/MD.00000000000006903>.
169. Wolfhagen N, Boldingh QJJ, de Lange M, Boermeester MA, de Jonge SW. Intraoperative redosing of surgical antibiotic prophylaxis in addition to preoperative prophylaxis versus single-dose prophylaxis for the prevention of surgical site infection: a meta-analysis and GRADE recommendation. *Ann Surg*. 2022;275:1050–7. <https://doi.org/10.1097/SLA.0000000000005436>.
170. Mazuski JE, Tessier JM, May AK, Sawyer RG, Nadler EP, Rosengart MR, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. *Surg Infect (Larchmt)*. 2017;18(1):1–76. <https://doi.org/10.1089/sur.2016.261>.
171. McCarty TP, White CM, Pappas PG. Candidemia and invasive candidiasis. *Infect Dis Clin N Am*. 2021;35(2):389–413. <https://doi.org/10.1016/j.idc.2021.03.007>.
172. Kollef MH, Shorr AF, Bassetti M, Timsit JF, Micek ST, Michelson AP, et al. Timing of antibiotic therapy in the ICU. *Crit Care*. 2021;25(1):360. <https://doi.org/10.1186/s13054-021-03787-z>.
173. Eachempati SR, Hydo LJ, Shou J, Barie PS. Does de-escalation of antibiotic therapy for ventilator-associated pneumonia affect the likelihood of recurrent pneumonia or mortality in critically ill surgical patients? *J Trauma*. 2009;66(5):1343–8. <https://doi.org/10.1097/TA.0b013e31819dca4e>.
174. Zanichelli V, Sharland M, Cappello B, Moja L, Getahun H, Pessoa-Silva C, et al. The WHO AWaRe (Access, Watch, Reserve) antibiotic book and prevention of antimicrobial resistance. *Bull World Health Organ*. 2023;101(4):290–6. <https://doi.org/10.2471/BLT.22.288614>.
175. Kumar A, Ellis P, Arabi Y, Roberts D, Light B, Parrillo JE, Cooperative Antimicrobial Therapy of Septic Shock Database Research Group, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock. *Chest*. 2009;136(5):1237–48. <https://doi.org/10.1378/chest.09-0087>.
176. Stuart B, Hounkpatin H, Becque T, Yao G, Zhu S, Alonso-Coello P, et al. Delayed antibiotic prescribing for respiratory tract infections: individual patient data meta-analysis. *BMJ*. 2021;373:n808. <https://doi.org/10.1136/bmj.n808>.
177. Hranjec T, Rosenberger LH, Swenson B, Metzger R, Flohr TR, Politano AD, et al. Aggressive versus conservative initiation of antimicrobial treatment in critically ill surgical patients with suspected intensive-care-unit-acquired infection: a quasi-experimental, before and after observational cohort study. *Lancet Infect Dis*. 2012;12(10):774–80. [https://doi.org/10.1016/S1473-3099\(12\)70151-2](https://doi.org/10.1016/S1473-3099(12)70151-2).
178. Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. *Antimicrob Agents Chemother*. 2010;54(11):4851–63. <https://doi.org/10.1128/AAC.00627-10>.
179. Bassetti M, Rello J, Blasi F, Goossens H, Sotgiu G, Tavoschi L, et al. Systematic review of the impact of appropriate versus inappropriate initial antibiotic therapy on outcomes of patients with severe bacterial infections. *Int J Antimicrob Agents*. 2020;56(6):106184. <https://doi.org/10.1016/j.ijantimicag.2020.106184>.
180. Weinberger J, Rhee C, Klompas M. A critical analysis of the literature on time-to-antibiotics in suspected sepsis. *J Infect Dis*. 2020;222(Suppl 2):S110–8. <https://doi.org/10.1093/infdis/jiaa146>.
181. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to treatment and mortality during mandated emergency care for sepsis. *N Engl J Med*. 2017;376(23):2235–44. <https://doi.org/10.1056/NEJMoa1703058>.
182. Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The timing of early antibiotics and hospital mortality in sepsis. *Am J Respir Crit Care Med*. 2017;196(7):856–63. <https://doi.org/10.1164/rccm.201609-1848OC>.
183. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock 2021. *Crit Care Med*. 2021;49(11):e1063–143. <https://doi.org/10.1097/CCM.00000000000005337>.

184. Blot S, Depuydt P, Vogelaers D, Decruyenaere J, De Waele J, Hoste E, et al. Colonization status and appropriate antibiotic therapy for nosocomial bacteremia caused by antibiotic-resistant gram-negative bacteria in an intensive care unit. *Infect Control Hosp Epidemiol*. 2005;26(6):575–9. <https://doi.org/10.1086/502575>.
185. Brusselaers N, Labeau S, Vogelaers D, Blot S. Value of lower respiratory tract surveillance cultures to predict bacterial pathogens in ventilator-associated pneumonia: systematic review and diagnostic test accuracy meta-analysis. *Intensive Care Med*. 2013;39(3):365–75. <https://doi.org/10.1007/s00134-012-2759-x>.
186. Michel F, Franceschini B, Berger P, Arnal JM, Gainnier M, Sainty JM, et al. Early antibiotic treatment for BAL-confirmed ventilator-associated pneumonia: a role for routine endotracheal aspirate cultures. *Chest*. 2005;127(2):589–97. <https://doi.org/10.1378/chest.127.2.589>.
187. Depuydt PO, Blot SI, Benoit DD, Claeys GW, Verschraegen GL, Vandewoude KH, et al. Antimicrobial resistance in nosocomial bloodstream infection associated with pneumonia and the value of systematic surveillance cultures in an adult intensive care unit. *Crit Care Med*. 2006;34(3):653–9. <https://doi.org/10.1097/01.CCM.0000201405.16525.34>.
188. Depuydt P, Benoit D, Vogelaers D, Decruyenaere J, Vandijck D, Claeys G, et al. Systematic surveillance cultures as a tool to predict involvement of multidrug antibiotic resistant bacteria in ventilator-associated pneumonia. *Intensive Care Med*. 2008;34(4):675–82. <https://doi.org/10.1007/s00134-007-0953-z>.
189. Müller M, Dela Peña A, Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. *Antimicrob Agents Chemother*. 2004;48:1441–53. <https://doi.org/10.1128/AAC.48.5.1441-1453.2004>.
190. Pea F, Viale P, Furlanut M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. *Clin Pharmacokinet*. 2005;44(10):1009–34. <https://doi.org/10.2165/00003088-200544100-00002>.
191. Gonzalez D, Schmidt S, Derendorf H. Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. *Clin Microbiol Rev*. 2013;26:274–88. <https://doi.org/10.1128/CMR.00092-12>.
192. Levison ME. Pharmacodynamics of antimicrobial drugs. *Infect Dis Clin Am*. 2004;18:451–65. <https://doi.org/10.1016/j.idc.2009.06.008>.
193. Buijk SL, Gyssens IC, Mouton RW, Van Vliet A, Verbrugh HA, Bruining HA. Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections. *J Antimicrob Chemother*. 2002;49:121–8. <https://doi.org/10.1093/jac/49.1.121>.
194. Dahyot-Fizelier C, Lefevre S, Laksiri L, Marchand S, Sawchuk RJ, Couet W, et al. Kinetics of imipenem distribution into the peritoneal fluid of patients with severe peritonitis studied by microdialysis. *Clin Pharmacokinet*. 2010;49:323–34. <https://doi.org/10.2165/001319370-000000000-00000>.
195. Karjagin J, Lefevre S, Oselin K, Kipper K, Marchand S, Tikkerber A, et al. Pharmacokinetics of meropenem determined by microdialysis in the peritoneal fluid of patients with severe peritonitis associated with septic shock. *Clin Pharmacol Ther*. 2008;83:452–9. <https://doi.org/10.1038/sj.clpt.6100312>.
196. Pea F, Viale P. Bench-to-bedside review: Appropriate antibiotic therapy in severe sepsis and septic shock—does the dose matter? *Crit Care*. 2009;13(3):214. <https://doi.org/10.1186/cc7774>.
197. Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. *Adv Drug Deliv Rev*. 2014;77:3–11. <https://doi.org/10.1016/j.addr.2014.07.006>.
198. Bland CM, Pai MP, Lodise TP. Reappraisal of contemporary pharmacokinetic and pharmacodynamic principles for informing aminoglycoside dosing. *Pharmacotherapy*. 2018;38(12):1229–38. <https://doi.org/10.1002/phar.2193>.
199. Pagkalis S, Mantadakis E, Mavros MN, Ammari C, Falagas ME. Pharmacological considerations for the proper clinical use of aminoglycosides. *Drugs*. 2011;71(17):2277–94. <https://doi.org/10.2165/0011597020-000000000-00000>.
200. Al-Dorzi HM, Al Harbi SA, Arabi YM. Antibiotic therapy of pneumonia in the obese patient: dosing and delivery. *Curr Opin Infect Dis*. 2014;27(2):165–73. <https://doi.org/10.1097/QCO.0000000000000045>.
201. Rybak MJ, Le J, Lodise TP, Levine DP, Bradley JS, Liu C, Mueller BA, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant *Staphylococcus aureus* infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. *Am J Health Syst Pharm*. 2020;77(11):835–64. <https://doi.org/10.1093/ajhp/xxaa036>.
202. McMullan BJ, Andresen D, Blyth CC, Avent ML, Bowen AC, Britton PN, et al. Antibiotic duration and timing of the switch from intravenous to oral route for bacterial infections in children: systematic review and guidelines. *Lancet Infect Dis*. 2016;16:E139–52. [https://doi.org/10.1016/S1473-3099\(16\)30024-X](https://doi.org/10.1016/S1473-3099(16)30024-X).
203. Landersdorfer CB, Gwee A, Nation RL. Clinical pharmacological considerations in an early intravenous to oral antibiotic switch: Are barriers real or simply perceived? *Clin Microbiol Infect*. 2023 Apr 12:S1198–743X(23)00179–9. doi: <https://doi.org/10.1016/j.cmi.2023.04.009>. Online ahead of print.
204. Quintiliani R, Grant E, Quintiliani R Jr. Transitional (intravenous to oral) antibiotic therapy. *J Med Liban*. 2000;48(4):233–40.
205. Al-Hasan MN, Rac H. Transition from intravenous to oral antimicrobial therapy in patients with uncomplicated and complicated bloodstream infections. *Clin Microbiol Infect*. 2020;26:299–306. <https://doi.org/10.1016/j.cmi.2019.05.012>.
206. Fishbein SRS, Mahmud B, Dantas G. Antibiotic perturbations to the gut microbiome. *Nat Rev Microbiol*. 2023. <https://doi.org/10.1038/s41579-023-00933-y>.
207. Tabah A, Bassetti M, Kollef MH, Zahar JR, Paiva JA, Timsit JF, et al. Antimicrobial de-escalation in critically ill patients: a position statement from a task force of the European Society of Intensive Care Medicine (ESICM) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Critically Ill Patients Study Group (ESGCIPI). *Intensive Care Med*. 2020;46(2):245–65. <https://doi.org/10.1007/s00134-019-05866-w>.
208. Silva BN, Andriolo RB, Atallah AN, Salomão R. De-escalation of antimicrobial treatment for adults with sepsis, severe sepsis or septic shock. *Cochrane Database Syst Rev*. 2013;2013(3):CD007934. <https://doi.org/10.1002/14651858.CD007934.pub3>.
209. Niederman MS. De-escalation therapy in ventilator-associated pneumonia. *Curr Opin Crit Care*. 2006;12(5):452–7. <https://doi.org/10.1097/01.ccx.0000244126.84989.a2>.
210. Rello J, Vidaur L, Sandiumenge A, Rodríguez A, Gualis B, Boque C, et al. De-escalation therapy in ventilator-associated pneumonia. *Crit Care Med*. 2004;32(11):2183–90. <https://doi.org/10.1097/01.ccm.0000145997.10438.28>.
211. De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions—a viewpoint of experts. *Intensive Care Med*. 2020;46(2):236–44. <https://doi.org/10.1007/s00134-019-05871-z>.
212. Lim C, Ashley EA, Hamers RL, Turner P, Kesteman T, Akech S, et al. Surveillance strategies using routine microbiology for antimicrobial resistance in low- and middle-income countries. *Clin Microbiol Infect*. 2021;27(10):1391–9. <https://doi.org/10.1016/j.cmi.2021.05.037>.
213. Cansizoglu MF, Tamer YT, Farid M, Koh AY, Toprak E. Rapid ultrasensitive detection platform for antimicrobial susceptibility testing. *PLoS Biol*. 2019;17(5):e3000291. <https://doi.org/10.1371/journal.pbio.3000291>.
214. Anjum MF, Zankari E, Hasman H. Molecular methods for detection of antimicrobial resistance. *Microbiol Spectr*. 2017. <https://doi.org/10.1128/microbiolspec.ARBA-0011-2017>.
215. Burnham CD, Leeds J, Nordmann P, O'Grady J, Patel J. Diagnosing antimicrobial resistance. *Nat Rev Microbiol*. 2017;15(11):697–703. <https://doi.org/10.1038/nrmicro.2017.103>.
216. Giordano C, Piccoli E, Brucculeri V, Barnini S. A prospective evaluation of two rapid phenotypical antimicrobial susceptibility technologies for the diagnostic stewardship of sepsis. *Biomed Res Int*. 2018;2018:6976923. <https://doi.org/10.1155/2018/6976923>.
217. Cals JW, Ament AJ, Hood K, Butler CC, Hopstaken RM, Wassink GF, et al. C-reactive protein point of care testing and physician communication skills training for lower respiratory tract infections in general practice:

- economic evaluation of a cluster randomized trial. *J Eval Clin Pract*. 2011;17(6):1059–69. <https://doi.org/10.1111/j.1365-2753.2010.01472.x>.
218. Holmes EAF, Harris SD, Hughes A, Craine N, Hughes DA. Cost-effectiveness analysis of the use of point-of-care C-reactive protein testing to reduce antibiotic prescribing in primary care. *Antibiotics* (Basel). 2018;7(4):106. <https://doi.org/10.3390/antibiotics7040106>.
 219. Hunter R. Cost-effectiveness of point-of-care C-reactive protein tests for respiratory tract infection in primary care in England. *Adv Ther*. 2015;32:69–85. <https://doi.org/10.1007/s12325-015-0180-x>.
 220. Global guidelines for the prevention of surgical site infection. Geneva: World Health Organization; 2018. Web Appendix 25. Summary of a systematic review on surgical antibiotic prophylaxis prolongation. <https://www.ncbi.nlm.nih.gov/books/NBK536429/>. Accessed 12 July 2023.
 221. Calderwood MS, Anderson DJ, Bratzler DW, Dellinger EP, Garcia-Houchins S, Maragakis LL, et al. Strategies to prevent surgical site infections in acute-care hospitals: 2022 Update. *Infect Control Hosp Epidemiol*. 2023;44(5):695–720. <https://doi.org/10.1017/ice.2023.67>.
 222. de Jonge SW, Boldingh QJJ, Solomkin JS, Dellinger EP, Egger M, Salanti G, et al. Effect of postoperative continuation of antibiotic prophylaxis on the incidence of surgical site infection: a systematic review and meta-analysis. *Lancet Infect Dis*. 2020;20(10):1182–92. [https://doi.org/10.1016/S1473-3099\(20\)30084-0](https://doi.org/10.1016/S1473-3099(20)30084-0).
 223. Branch-Elliman W, O'Brien W, Strymish J, Itani K, Wyatt C, Gupta K. Association of duration and type of surgical prophylaxis with antimicrobial-associated adverse events. *JAMA Surg*. 2019;154:590–8. <https://doi.org/10.1001/jamasurg.2019.0569>.
 224. Brink AJ, Messina AP, Feldman C, Richards GA, van den Bergh D, Netcare Antimicrobial Stewardship Study Alliance. From guidelines to practice: a pharmacist-driven prospective audit and feedback improvement model for peri-operative antibiotic prophylaxis in 34 South African hospitals. *J Antimicrob Chemother*. 2017;72(4):1227–34. <https://doi.org/10.1093/jac/dkw523>.
 225. Spellberg B, Rice LB. Duration of antibiotic therapy: shorter is better. *Ann Intern Med*. 2019;171(3):210–1. <https://doi.org/10.7326/M19-1509>.
 226. Langford BJ, Nisenbaum R, Brown KA, Chan A, Downing M. Antibiotics: easier to start than to stop? Predictors of antimicrobial stewardship recommendation acceptance. *Clin Microbiol Infect*. 2020;26(12):1638–43. <https://doi.org/10.1016/j.cmi.2020.07.048>.
 227. Spellberg B. The new antibiotic mantra “shorter is better.” *JAMA Intern Med*. 2016;176(9):1254–5. <https://doi.org/10.1001/jamainternmed.2016.3646>.
 228. Sawyer RG, Claridge JA, Nathens AB, Rotstein OD, Duane TM, Evans HL, STOP-IT Trial Investigators, et al. Trial of short-course antimicrobial therapy for intraabdominal infection. *N Engl J Med*. 2015;372(21):1996–2005. <https://doi.org/10.1056/NEJMoa1411162>.
 229. Montravers P, Tubach F, Lescot T, Veber B, Esposito-Farèse M, Seguin P, et al. Short-course antibiotic therapy for critically ill patients treated for postoperative intra-abdominal infection: the DURAPOD randomised clinical trial. *Intensive Care Med*. 2018;44(3):300–10. <https://doi.org/10.1007/s00134-018-5088-x>.
 230. Chastre J, Wolff M, Fagon JY, Chevret S, Thomas F, Wermert D, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. *JAMA*. 2003;290(19):2588–98. <https://doi.org/10.1001/jama.290.19.2588>.
 231. Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. *Chest*. 2013;144(6):1759–67. <https://doi.org/10.1378/chest.13-0076>.
 232. Martin-Loeches I, Rodriguez AH, Torres A. New guidelines for hospital-acquired pneumonia/ventilator-associated pneumonia: USA vs. Europe. *Curr Opin Crit Care*. 2018;24(5):347–52. <https://doi.org/10.1097/MCC.0000000000000535>.
 233. Mo Y, West TE, MacLaren G, Booraphun S, Li AY, Kayastha G, et al. Reducing antibiotic treatment duration for ventilator-associated pneumonia (REGARD-VAP): a trial protocol for a randomised clinical trial. *BMJ Open*. 2021;11(5):e050105. <https://doi.org/10.1136/bmjopen-2021-050105>.
 234. Yahav D, Franceschini E, Koppel F, Turjeman A, Babich T, Bitterman R, et al. Seven versus 14 days of antibiotic therapy for uncomplicated gram-negative bacteremia: a noninferiority randomized controlled trial. *Clin Infect Dis*. 2019;69(7):1091–8. <https://doi.org/10.1093/cid/ciy1054>.
 235. Daneman N, Rishu AH, Pinto R, Aslanian P, Bagshaw SM, Carignan A, et al. 7 versus 14 days of antibiotic treatment for critically ill patients with bloodstream infection: a pilot randomized clinical trial. *Trials*. 2018;19(1):111. <https://doi.org/10.1186/s13063-019-4033-9>.
 236. Chotiprasitsakul D, Han JH, Cosgrove SE, Harris AD, Lautenbach E, Conley AT, et al. Comparing the outcomes of adults with Enterobacteriaceae bacteremia receiving short-course versus prolonged-course antibiotic therapy in a multicenter, propensity score-matched cohort. *Clin Infect Dis*. 2018;66(2):172–7. <https://doi.org/10.1093/cid/cix767>.
 237. Tansarli GS, Andreatos N, Pliakos EE, Mylonakis E. A systematic review and meta-analysis of antibiotic treatment duration for bacteremia due to Enterobacteriaceae. *Antimicrob Agents Chemother*. 2019;63(5):e02495–e2518. <https://doi.org/10.1128/AAC.02495-18>.
 238. Fabre V, Amoah J, Cosgrove SE, Tamma PD. Antibiotic therapy for *Pseudomonas aeruginosa* bloodstream infections: How long is long enough? *Clin Infect Dis*. 2019;69(11):2011–4. <https://doi.org/10.1093/cid/ciz223>.
 239. von Dach E, Albrich WC, Brunel AS, Prendki V, Cuvelier C, Flury D, et al. Effect of C-reactive protein-guided antibiotic treatment duration, 7-day treatment, or 14-day treatment on 30-day clinical failure rate in patients with uncomplicated gram-negative bacteremia: a randomized clinical trial. *JAMA*. 2020;323(21):2160–9. <https://doi.org/10.1001/jama.2020.6348>.
 240. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. *Arch Intern Med*. 2004;164(15):1669–74. <https://doi.org/10.1001/archinte.164.15.1669>.
 241. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Infectious Diseases Society of America, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis*. 2014;59(2):e10–52. <https://doi.org/10.1093/cid/ciu444>.
 242. Brink AJ, Richards G. Best practice: antibiotic decision-making in ICUs. *Curr Opin Crit Care*. 2020;26(5):478–88. <https://doi.org/10.1097/MCC.0000000000000752>.
 243. Khilnani GC, Tiwari P, Zirpe KG, Chaudhry D, Govil D, Dixit S, et al. Guidelines for the use of procalcitonin for rational use of antibiotics. *Indian J Crit Care Med*. 2022;26(Suppl 2):S77–94. <https://doi.org/10.5005/jp-journals-10071-24326>.
 244. Wirz J, Meier MA, Bouadma L, Luyt CE, Wolff M, Chastre J, et al. Effect of procalcitonin-guided antibiotic treatment on clinical outcomes in intensive care unit patients with infection and sepsis patients: a patient-level meta-analysis of randomized trials. *Crit Care*. 2018;22(1):191. <https://doi.org/10.1186/s13054-018-2125-2127>.
 245. Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, et al. WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections. *World J Emerg Surg*. 2022;17(1):3. <https://doi.org/10.1186/s13017-022-00406-2>.
 246. Sartelli M, Coccolini F, Kluger Y, Agastra E, Abu-Zidan FM, Abbas AES, et al. WSES/GAIS/SIS-E/WSIS/AAST global clinical pathways for patients with intra-abdominal infections. *World J Emerg Surg*. 2021;16(1):49. <https://doi.org/10.1186/s13017-021-00387-8>.
 247. Kao LS, Ball CG, Chaudhury PK, for Members of the Evidence Based Reviews in Surgery Group. Evidence-based reviews in surgery: Early cholecystectomy for cholecystitis. *Ann Surg*. 2018;268(6):940–2. <https://doi.org/10.1097/SLA.0000000000002867>.
 248. De Waele JJ. Early source control in sepsis. *Langenbecks Arch Surg*. 2010;395:489–94. <https://doi.org/10.1007/s00423-010-0650-1>.
 249. Martínez ML, Ferrer R, Torrents E, Guillaumat-Prats R, Gomà G, Suárez D, et al. Impact of source control in patients with severe sepsis and septic shock. *Crit Care Med*. 2017;45(1):11–9. <https://doi.org/10.1097/CCM.0000000000002011>.
 250. Bloos F, Rüddel H, Thomas-Rüddel D, Schwarzkopf D, Pausch C, Harbarth S, et al. Effect of a multifaceted educational intervention for anti-infectious measures on sepsis mortality: a cluster randomized trial. *Intensive Care Med*. 2017;43(11):1602–12. <https://doi.org/10.1007/s00134-017-4782-4>.
 251. Reitz KM, Kennedy J, Li SR, Handzel R, Tonetti DA, Neal MD, et al. association between time to source control in sepsis and 90-day mortality. *JAMA Surg*. 2022;157(9):817–26. <https://doi.org/10.1001/jamasurg.2022.2761>.

252. De Pascale G, Antonelli M, Deschepper M, Arvaniti K, Blot K, Brown BC, et al. Poor timing and failure of source control are risk factors for mortality in critically ill patients with secondary peritonitis. *Intensive Care Med*. 2022;48(11):1593–606. <https://doi.org/10.1007/s00134-022-06883-y>.
253. Tabah A, Buetti N, Staiquily Q, EUROBACT-2 Study Group, ESICM, ESCMID ESGCIP and the OUTCOMEREA Network, et al. Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study. *Intensive Care Med*. 2023. <https://doi.org/10.1007/s00134-012-2695-9>.
254. De Waele JJ, Girardis M, Martin-Loeches I. Source control in the management of sepsis and septic shock. *Intensive Care Med*. 2023;48(12):1799–802. <https://doi.org/10.1007/s00134-022-06852-5>.
255. Barie PS, Williams MD, McCollam JS, Bates BM, Quilty RL, Lowry SF, PROWESS Surgical Evaluation Committee, et al. Benefit/risk profile of drotrecogin alfa (activated) in surgical patients with severe sepsis. *Am J Surg*. 2004;188(3):212–20. <https://doi.org/10.1016/j.amjsurg.2004.06.008>.
256. van de Groep K, Verhoeff TL, Verboom DM, Bos LD, Schultz MJ, Bonten MJM, et al. Epidemiology and outcomes of source control procedures in critically ill patients with intra-abdominal infection. *J Crit Care*. 2019;52:258–64. <https://doi.org/10.1016/j.jccr.2019.02.029>.
257. European Center for Disease Prevention and Control. Healthcare-associated infections surveillance network (HAI-Net). <https://www.ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/hai-net>. Accessed 12 July 2023.
258. Centers for Disease Control and Prevention. National Healthcare Safety Network (NHSN). <https://www.cdc.gov/nhsn/index.html>. Accessed 12 July 2023.
259. European Center for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022–2020 data. www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data. Accessed 12 July 2023.
260. Global antimicrobial resistance and use surveillance system (GLASS) report: 2022. Geneva: World Health Organization; 2022. www.who.int/publications/i/item/9789240062702. Accessed 12 July 2023.
261. Maugeri A, Barchitta M, Puglisi F, Agodi A. Socio-economic, governance and health indicators shaping antimicrobial resistance: an ecological analysis of 30 European countries. *Glob Health*. 2023;19(1):12. <https://doi.org/10.1186/s12992-023-00913-0>.
262. Pallares C, Hernández-Gómez C, Appel TM, Escandón K, Reyes S, Salcedo S, et al. Impact of antimicrobial stewardship programs on antibiotic consumption and antimicrobial resistance in four Colombian healthcare institutions. *BMC Infect Dis*. 2022;22(1):420. <https://doi.org/10.1186/s12879-022-07410-6>.
263. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. *Proc Natl Acad Sci USA*. 2018;115(15):E3463–70. <https://doi.org/10.1073/pnas.1717295115>.
264. Rawson TM, Moore LS, Tivey AM, Tsao A, Gilchrist M, Charani E, et al. Behaviour change interventions to influence antimicrobial prescribing: a cross-sectional analysis of reports from UK state-of-the-art scientific conferences. *Antimicrob Resist Infect Control*. 2017;6(1):11. <https://doi.org/10.1186/s13756-019-0603-6>.
265. Majumder MAA, Rahman S, Cohall D, Bharatha A, Singh K, Haque M, Gittens-St Hilaire M. Antimicrobial stewardship: fighting antimicrobial resistance and protecting global public health. *Infect Drug Resist*. 2020;13:4713–38. <https://doi.org/10.2147/IDR.S290835>.
266. Majumder MAA, Singh K, Hilaire MG, Rahman S, Sa B, Haque M. Tackling antimicrobial resistance by promoting antimicrobial stewardship in medical and allied health professional curricula. *Expert Rev Anti Infect Ther*. 2020;18(12):1245–58. <https://doi.org/10.1080/14787210.2020.1796638>.
267. Alkhuzaei AMJB, Salama RE, Eljak IEI, Chehab MA, Selim NA. Perceptions and practice of physicians and pharmacists regarding antibiotic misuse at primary health centres in Qatar: a cross-sectional study. *J Taibah Univ Med Sci*. 2017;13(1):77–82. <https://doi.org/10.1016/j.jtumed.2017.09.001>.
268. Mangione SR, McGlynn E, Elliot M. Parent expectations for antibiotics, physician–parent communication, and satisfaction. *Arch Pediatr Adolesc Med*. 2001;7(155):800–6.
269. Saleem Z, Godman B, Cook A, et al. Ongoing efforts to improve antimicrobial utilization in hospitals among African countries and implications for the future. *Antibiotics (Basel)*. 2022;11(12):1824. <https://doi.org/10.3390/antibiotics11121824>.
270. Sartelli M, Labricciosa FM, Barbadoro P, Pagani L, Ansaloni L, Brink AJ, et al. The global alliance for infections in surgery: defining a model for antimicrobial stewardship—results from an international cross-sectional survey. *World J Emerg Surg*. 2017;12:34. <https://doi.org/10.1186/s13017-017-0145-2>.
271. Davey P, Brown E, Charani E, Fenelon L, Gould IM, Holmes A, et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. *Cochrane Database Syst Rev*. 2013;4:CD003543. <https://doi.org/10.1002/14651858.CD003543.pub4>.
272. Rawson TM, Moore LS, Gilchrist MJ, Holmes AH. Antimicrobial stewardship: Are we failing in cross-specialty clinical engagement? *J Antimicrob Chemother*. 2016;71:554–9. <https://doi.org/10.1093/jac/dkv337>.
273. Howard P, Pulcini C, Levy Hara G, West RM, Gould IM, Harbarth S, et al. An international cross-sectional survey of antimicrobial stewardship programmes in hospitals. *J Antimicrob Chemother*. 2015;70(4):1245–55. <https://doi.org/10.1093/jac/dku497>.
274. Raval MV, Bentrem DJ, Eskandari MK, Ingraham AM, Hall BL, Randolph B, et al. The role of surgical champions in the American College of Surgeons National Surgical Quality Improvement Program—a national survey. *J Surg Res*. 2011;166(1):e15–25. <https://doi.org/10.1016/j.jss.2010.10.036>.
275. Wunderink RG, Srinivasan A, Barie PS, Chastre J, Dela Cruz CS, Douglas IS, et al. Antibiotic stewardship in the intensive care unit. An official American Thoracic Society workshop report in collaboration with the AACN, CHEST, CDC, and SCCM. *Ann Am Thorac Soc*. 2020;17(5):531–40. <https://doi.org/10.1513/AnnalsATS.202003-188ST>.
276. May L, Martín Quirós A, Ten Oever J, Hoogerwerf J, Schoffelen T, Schouten J. Antimicrobial stewardship in the emergency department: characteristics and evidence for effectiveness of interventions. *Clin Microbiol Infect*. 2021;27(2):204–9. <https://doi.org/10.1016/j.cmi.2020.10.028>.
277. Paul M, Pulia M, Pulcini C. Antibiotic stewardship in the emergency department: not to be overlooked. *Clin Microbiol Infect*. 2021;27(2):172–4. <https://doi.org/10.1016/j.cmi.2020.11.015>.
278. Castro-Sánchez E, Gilchrist M, Ahmad R, Courtenay M, Bosanquet J, Holmes AH. Nurse roles in antimicrobial stewardship: lessons from public sectors models of acute care service delivery in the United Kingdom. *Antimicrob Resist Infect Control*. 2019;22(8):162.
279. Kumar M, Sarma DK, Shubham S, Kumawat M, Verma V, Nina PB, et al. Futuristic non-antibiotic therapies to combat antibiotic resistance: a review. *Front Microbiol*. 2021;12:609459. <https://doi.org/10.3389/fmicb.2021.609459>.
280. Catho G, Sauser J, Coray V, Da Silva S, Elzi L, Harbarth S, et al. Impact of interactive computerised decision support for hospital antibiotic use (COMPASS): an open-label, cluster-randomised trial in three Swiss hospitals. *Lancet Infect Dis*. 2022;22(10):1493–502. [https://doi.org/10.1016/S1473-3099\(22\)00308-5](https://doi.org/10.1016/S1473-3099(22)00308-5).
281. Curtis CE, Al Bahar F, Marriott JF. The effectiveness of computerised decision support on antibiotic use in hospitals: a systematic review. *PLoS ONE*. 2017;12(8):e0183062. <https://doi.org/10.1371/journal.pone.0183062>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.